Functional classification of arterial grafts according to physiological and pharmacological contractility, anatomical, and embryological characteristic
\r\n\r\n
\r\n\r\nThis project was co-financed by the European Regional Development Fund under the Operational Programme "Innovative Economy".\r\n',isbn:null,printIsbn:"978-953-51-1734-6",pdfIsbn:"978-953-51-4230-0",doi:"10.5772/59798",price:119,priceEur:129,priceUsd:155,slug:"storage-stability-of-fuels",numberOfPages:278,isOpenForSubmission:!1,isInWos:1,hash:"bc73beb5dc74410e15c8ee19ee4de722",bookSignature:"Krzysztof Biernat",publishedDate:"February 4th 2015",coverURL:"https://cdn.intechopen.com/books/images_new/4751.jpg",numberOfDownloads:16980,numberOfWosCitations:11,numberOfCrossrefCitations:10,numberOfDimensionsCitations:21,hasAltmetrics:1,numberOfTotalCitations:42,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"October 30th 2014",dateEndSecondStepPublish:"November 20th 2014",dateEndThirdStepPublish:"February 24th 2015",dateEndFourthStepPublish:"May 25th 2015",dateEndFifthStepPublish:"June 24th 2015",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6,7,8",editedByType:"Edited by",kuFlag:!1,editors:[{id:"155009",title:"Prof.",name:"Krzysztof",middleName:null,surname:"Biernat",slug:"krzysztof-biernat",fullName:"Krzysztof Biernat",profilePictureURL:"https://mts.intechopen.com/storage/users/155009/images/system/155009.jfif",biography:"Krzysztof Biernat Ph.D. (Mech.Eng.) is a professor of the Automotive Industry Institute (PIMOT), acting as President of the Polish Biomethane Council, a Coordinator of Polish Technology Platform for Biofuels, and a member of the Coordinating Committee of Society Cluster of Bioeconomy. He is also a lead expert of the International Renewable Energy Agency and an expert in many operational programs. He specialized in chemical thermodynamics of environmental processes as well as obtaining technologies, quality evaluation, and the use of exploitative liquids, including biofuels, and biorefinery systems. He is an author of above 200 publications in the area of properties and exploitative conditionings of fuels, biofuels, and other liquids as well as environmental protection. He is a member of many national and international scientific societies including the American Chemical Society and American Association for the Advancement of Science.",institutionString:"Łukasiewicz R&D Network - Automotive Industry Institute",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"5",totalChapterViews:"0",totalEditedBooks:"5",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"768",title:"Petroleum Engineering",slug:"engineering-energy-engineering-petroleum-engineering"}],chapters:[{id:"47905",title:"The Influence of Engine Fuel Manufacturing Processes on Their Performance Properties in Operating Conditions",doi:"10.5772/59800",slug:"the-influence-of-engine-fuel-manufacturing-processes-on-their-performance-properties-in-operating-co",totalDownloads:1874,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Krzysztof Biernat",downloadPdfUrl:"/chapter/pdf-download/47905",previewPdfUrl:"/chapter/pdf-preview/47905",authors:[{id:"174229",title:"M.Sc.",name:"Dorota",surname:"Wardzińska",slug:"dorota-wardzinska",fullName:"Dorota Wardzińska"}],corrections:null},{id:"47911",title:"Criteria for the Quality Assessment of Engine Fuels in Storage and Operating Conditions",doi:"10.5772/59801",slug:"criteria-for-the-quality-assessment-of-engine-fuels-in-storage-and-operating-conditions",totalDownloads:1412,totalCrossrefCites:0,totalDimensionsCites:1,signatures:"Krzysztof Biernat",downloadPdfUrl:"/chapter/pdf-download/47911",previewPdfUrl:"/chapter/pdf-preview/47911",authors:[{id:"174229",title:"M.Sc.",name:"Dorota",surname:"Wardzińska",slug:"dorota-wardzinska",fullName:"Dorota Wardzińska"}],corrections:null},{id:"47819",title:"Biofuels in Storage and Operating Conditions",doi:"10.5772/59802",slug:"biofuels-in-storage-and-operating-conditions",totalDownloads:1567,totalCrossrefCites:2,totalDimensionsCites:3,signatures:"Krzysztof Biernat",downloadPdfUrl:"/chapter/pdf-download/47819",previewPdfUrl:"/chapter/pdf-preview/47819",authors:[{id:"174229",title:"M.Sc.",name:"Dorota",surname:"Wardzińska",slug:"dorota-wardzinska",fullName:"Dorota Wardzińska"}],corrections:null},{id:"47914",title:"Liquid Fuel Ageing Processes in Long-term Storage Conditions",doi:"10.5772/59799",slug:"liquid-fuel-ageing-processes-in-long-term-storage-conditions",totalDownloads:2463,totalCrossrefCites:1,totalDimensionsCites:4,signatures:"Marlena Owczuk and Krzysztof Kołodziejczyk",downloadPdfUrl:"/chapter/pdf-download/47914",previewPdfUrl:"/chapter/pdf-preview/47914",authors:[{id:"174229",title:"M.Sc.",name:"Dorota",surname:"Wardzińska",slug:"dorota-wardzinska",fullName:"Dorota Wardzińska"}],corrections:null},{id:"47919",title:"Corrosiveness of Fuels During Storage Processes",doi:"10.5772/59803",slug:"corrosiveness-of-fuels-during-storage-processes",totalDownloads:2965,totalCrossrefCites:1,totalDimensionsCites:3,signatures:"Monika Ziółkowska and Dorota Wardzińska",downloadPdfUrl:"/chapter/pdf-download/47919",previewPdfUrl:"/chapter/pdf-preview/47919",authors:[{id:"174229",title:"M.Sc.",name:"Dorota",surname:"Wardzińska",slug:"dorota-wardzinska",fullName:"Dorota Wardzińska"}],corrections:null},{id:"47921",title:"Autoxidation of Fuels During Storage",doi:"10.5772/59807",slug:"autoxidation-of-fuels-during-storage",totalDownloads:2072,totalCrossrefCites:2,totalDimensionsCites:4,signatures:"Joanna Czarnocka, Anna Matuszewska and Małgorzata\nOdziemkowska",downloadPdfUrl:"/chapter/pdf-download/47921",previewPdfUrl:"/chapter/pdf-preview/47921",authors:[{id:"174229",title:"M.Sc.",name:"Dorota",surname:"Wardzińska",slug:"dorota-wardzinska",fullName:"Dorota Wardzińska"}],corrections:null},{id:"47922",title:"A Review of Selected Methods of Measurement Used for the On-Line Analysis of Liquid Fuels",doi:"10.5772/59804",slug:"a-review-of-selected-methods-of-measurement-used-for-the-on-line-analysis-of-liquid-fuels",totalDownloads:1570,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Artur Malinowski, Paweł Wrzosek, Anna Turlej and Dorota\nWardzińska",downloadPdfUrl:"/chapter/pdf-download/47922",previewPdfUrl:"/chapter/pdf-preview/47922",authors:[{id:"174229",title:"M.Sc.",name:"Dorota",surname:"Wardzińska",slug:"dorota-wardzinska",fullName:"Dorota Wardzińska"}],corrections:null},{id:"47923",title:"Analysis of Changes in the Properties of Selected Chemical Compounds and Motor Fuels Taking Place During Oxidation Processes",doi:"10.5772/59805",slug:"analysis-of-changes-in-the-properties-of-selected-chemical-compounds-and-motor-fuels-taking-place-du",totalDownloads:1328,totalCrossrefCites:3,totalDimensionsCites:4,signatures:"Marta Skolniak, Paweł Bukrejewski and Jarosław Frydrych",downloadPdfUrl:"/chapter/pdf-download/47923",previewPdfUrl:"/chapter/pdf-preview/47923",authors:[{id:"174229",title:"M.Sc.",name:"Dorota",surname:"Wardzińska",slug:"dorota-wardzinska",fullName:"Dorota Wardzińska"}],corrections:null},{id:"47924",title:"Environmental Aspects in the Life Cycle of Liquid Biofuels with Biocomponents, Taking into Account the Storage Process",doi:"10.5772/59806",slug:"environmental-aspects-in-the-life-cycle-of-liquid-biofuels-with-biocomponents-taking-into-account-th",totalDownloads:1737,totalCrossrefCites:1,totalDimensionsCites:2,signatures:"Izabela Samson-Bręk, Barbara Smerkowska and Aleksandra Filip",downloadPdfUrl:"/chapter/pdf-download/47924",previewPdfUrl:"/chapter/pdf-preview/47924",authors:[{id:"174229",title:"M.Sc.",name:"Dorota",surname:"Wardzińska",slug:"dorota-wardzinska",fullName:"Dorota Wardzińska"}],corrections:null}],productType:{id:"3",title:"Monograph",chapterContentType:"chapter",authoredCaption:"Authored by"}},relatedBooks:[{type:"book",id:"4542",title:"Biofuels",subtitle:"Status and Perspective",isOpenForSubmission:!1,hash:"cbcf6eb3ffef503058cdf579d9d7fc63",slug:"biofuels-status-and-perspective",bookSignature:"Krzysztof Biernat",coverURL:"https://cdn.intechopen.com/books/images_new/4542.jpg",editedByType:"Edited by",editors:[{id:"155009",title:"Prof.",name:"Krzysztof",surname:"Biernat",slug:"krzysztof-biernat",fullName:"Krzysztof Biernat"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6784",title:"Biofuels",subtitle:"State of Development",isOpenForSubmission:!1,hash:"9a31143f106bba91ce8430f49d3339af",slug:"biofuels-state-of-development",bookSignature:"Krzysztof Biernat",coverURL:"https://cdn.intechopen.com/books/images_new/6784.jpg",editedByType:"Edited by",editors:[{id:"155009",title:"Prof.",name:"Krzysztof",surname:"Biernat",slug:"krzysztof-biernat",fullName:"Krzysztof Biernat"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5087",title:"Alternative Fuels",subtitle:"Technical and Environmental Conditions",isOpenForSubmission:!1,hash:"d384e15f7ac163a7323b08fede906b7a",slug:"alternative-fuels-technical-and-environmental-conditions",bookSignature:"Krzysztof Biernat",coverURL:"https://cdn.intechopen.com/books/images_new/5087.jpg",editedByType:"Edited by",editors:[{id:"155009",title:"Prof.",name:"Krzysztof",surname:"Biernat",slug:"krzysztof-biernat",fullName:"Krzysztof Biernat"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"3",chapterContentType:"chapter",authoredCaption:"Authored by"}},{type:"book",id:"8150",title:"Elements of Bioeconomy",subtitle:null,isOpenForSubmission:!1,hash:"f5a930b0695ff23259fe96f219ff9a15",slug:"elements-of-bioeconomy",bookSignature:"Krzysztof Biernat",coverURL:"https://cdn.intechopen.com/books/images_new/8150.jpg",editedByType:"Edited by",editors:[{id:"155009",title:"Prof.",name:"Krzysztof",surname:"Biernat",slug:"krzysztof-biernat",fullName:"Krzysztof Biernat"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5811",title:"Recent Insights in Petroleum Science and Engineering",subtitle:null,isOpenForSubmission:!1,hash:"33b7777178f4a179ba475e3e15405427",slug:"recent-insights-in-petroleum-science-and-engineering",bookSignature:"Mansoor Zoveidavianpoor",coverURL:"https://cdn.intechopen.com/books/images_new/5811.jpg",editedByType:"Edited by",editors:[{id:"92105",title:"Dr.",name:"Mansoor",surname:"Zoveidavianpoor",slug:"mansoor-zoveidavianpoor",fullName:"Mansoor Zoveidavianpoor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6466",title:"Shale Gas",subtitle:"New Aspects and Technologies",isOpenForSubmission:!1,hash:"02763c6398f049c222acf6a774dd38ee",slug:"shale-gas-new-aspects-and-technologies",bookSignature:"Ali Al-Juboury",coverURL:"https://cdn.intechopen.com/books/images_new/6466.jpg",editedByType:"Edited by",editors:[{id:"58570",title:"Prof.",name:"Ali",surname:"Al-Juboury",slug:"ali-al-juboury",fullName:"Ali Al-Juboury"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7609",title:"Enhanced Oil Recovery Processes",subtitle:"New Technologies",isOpenForSubmission:!1,hash:"62359d9c21b76f899be04fa0f8b46668",slug:"enhanced-oil-recovery-processes-new-technologies",bookSignature:"Ariffin Samsuri",coverURL:"https://cdn.intechopen.com/books/images_new/7609.jpg",editedByType:"Edited by",editors:[{id:"120519",title:"Prof.",name:"Ariffin",surname:"Samsuri",slug:"ariffin-samsuri",fullName:"Ariffin Samsuri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7314",title:"Exploitation of Unconventional Oil and Gas Resources",subtitle:"Hydraulic Fracturing and Other Recovery and Assessment Techniques",isOpenForSubmission:!1,hash:"2eba15587cac74206f978e72a0cef2f9",slug:"exploitation-of-unconventional-oil-and-gas-resources-hydraulic-fracturing-and-other-recovery-and-assessment-techniques",bookSignature:"Kenneth Imo-Imo Eshiet",coverURL:"https://cdn.intechopen.com/books/images_new/7314.jpg",editedByType:"Edited by",editors:[{id:"195037",title:"Dr.",name:"Kenneth Imo-Imo Israel",surname:"Eshiet",slug:"kenneth-imo-imo-israel-eshiet",fullName:"Kenneth Imo-Imo Israel Eshiet"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"64875",slug:"erratum-introductory-chapter-primary-concept-of-hypoxia-and-anoxia",title:"Erratum - Introductory Chapter: Primary Concept of Hypoxia and Anoxia",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/64875.pdf",downloadPdfUrl:"/chapter/pdf-download/64875",previewPdfUrl:"/chapter/pdf-preview/64875",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/64875",risUrl:"/chapter/ris/64875",chapter:{id:"62932",slug:"introductory-chapter-primary-concept-of-hypoxia-and-anoxia",signatures:"Shrilaxmi Bagali, Gavishsidappa A. Hadimani, Mallanagouda S. Biradar and Kusal K. Das",dateSubmitted:"June 18th 2018",dateReviewed:"July 12th 2018",datePrePublished:"November 5th 2018",datePublished:"December 12th 2018",book:{id:"7009",title:"Hypoxia and Anoxia",subtitle:null,fullTitle:"Hypoxia and Anoxia",slug:"hypoxia-and-anoxia",publishedDate:"December 12th 2018",bookSignature:"Kusal K. Das and Mallanagouda Shivanagouda Biradar",coverURL:"https://cdn.intechopen.com/books/images_new/7009.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"187859",title:"Prof.",name:"Kusal",middleName:"K.",surname:"Das",slug:"kusal-das",fullName:"Kusal Das"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"187859",title:"Prof.",name:"Kusal",middleName:"K.",surname:"Das",fullName:"Kusal Das",slug:"kusal-das",email:"kusaldas@yahoo.com",position:null,institution:{name:"University of Leeds",institutionURL:null,country:{name:"United Kingdom"}}},{id:"188854",title:"Prof.",name:"M.S.",middleName:null,surname:"Biradar",fullName:"M.S. Biradar",slug:"m.s.-biradar",email:"editor.bjhs@bldeuniversity.ac.in",position:null,institution:null},{id:"263841",title:"Dr.",name:"Shrilaxmi",middleName:null,surname:"Bagali",fullName:"Shrilaxmi Bagali",slug:"shrilaxmi-bagali",email:"shrikots@yahoo.in",position:null,institution:null},{id:"265434",title:"Dr.",name:"Gavishiddappa A.",middleName:null,surname:"Hadimani",fullName:"Gavishiddappa A. Hadimani",slug:"gavishiddappa-a.-hadimani",email:"gavish.hadimani@yahoo.com",position:null,institution:null}]}},chapter:{id:"62932",slug:"introductory-chapter-primary-concept-of-hypoxia-and-anoxia",signatures:"Shrilaxmi Bagali, Gavishsidappa A. Hadimani, Mallanagouda S. Biradar and Kusal K. Das",dateSubmitted:"June 18th 2018",dateReviewed:"July 12th 2018",datePrePublished:"November 5th 2018",datePublished:"December 12th 2018",book:{id:"7009",title:"Hypoxia and Anoxia",subtitle:null,fullTitle:"Hypoxia and Anoxia",slug:"hypoxia-and-anoxia",publishedDate:"December 12th 2018",bookSignature:"Kusal K. Das and Mallanagouda Shivanagouda Biradar",coverURL:"https://cdn.intechopen.com/books/images_new/7009.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"187859",title:"Prof.",name:"Kusal",middleName:"K.",surname:"Das",slug:"kusal-das",fullName:"Kusal Das"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"187859",title:"Prof.",name:"Kusal",middleName:"K.",surname:"Das",fullName:"Kusal Das",slug:"kusal-das",email:"kusaldas@yahoo.com",position:null,institution:{name:"University of Leeds",institutionURL:null,country:{name:"United Kingdom"}}},{id:"188854",title:"Prof.",name:"M.S.",middleName:null,surname:"Biradar",fullName:"M.S. Biradar",slug:"m.s.-biradar",email:"editor.bjhs@bldeuniversity.ac.in",position:null,institution:null},{id:"263841",title:"Dr.",name:"Shrilaxmi",middleName:null,surname:"Bagali",fullName:"Shrilaxmi Bagali",slug:"shrilaxmi-bagali",email:"shrikots@yahoo.in",position:null,institution:null},{id:"265434",title:"Dr.",name:"Gavishiddappa A.",middleName:null,surname:"Hadimani",fullName:"Gavishiddappa A. Hadimani",slug:"gavishiddappa-a.-hadimani",email:"gavish.hadimani@yahoo.com",position:null,institution:null}]},book:{id:"7009",title:"Hypoxia and Anoxia",subtitle:null,fullTitle:"Hypoxia and Anoxia",slug:"hypoxia-and-anoxia",publishedDate:"December 12th 2018",bookSignature:"Kusal K. Das and Mallanagouda Shivanagouda Biradar",coverURL:"https://cdn.intechopen.com/books/images_new/7009.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"187859",title:"Prof.",name:"Kusal",middleName:"K.",surname:"Das",slug:"kusal-das",fullName:"Kusal Das"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"7471",leadTitle:null,title:"Advanced Surface Engineering Research",subtitle:null,reviewType:"peer-reviewed",abstract:"Surface engineering has rapidly expanded in recent years as the demand for improved materials has increased. Surface engineering is a valuable tool for conceiving both surface and bulk properties, which cannot be achieved simultaneously either by the coating material or by the substrate material alone. The book is written on the current trends of surface engineering and relevant research. The applied and basic research as well as some worthy concepts of materials related to this area is explained clearly to understand the need for surface engineering in industrial applications. The different surface modification processes, properties, and their characterizations are discussed elaborately for future research and as a text book. Modification of surface properties by films or coatings is used in industrial applications. This is an area of interest to numerous fields: fabrication of parts, mechanics, transport, catalysis, energy, production, microelectronics, optoelectronics, the leisure industry, etc. The properties are considered for protection against corrosion, oxidation or wear, biocompatibility, wetting, adhesion, durability, catalytic activity, and toughness. The modern concept of engineering is discussed to ensure that the contributions of this subject minimize energy consumption. The book will be used as a state of the art for present and future researchers, industrial components design, and control.",isbn:"978-1-78984-340-8",printIsbn:"978-1-78984-339-2",pdfIsbn:"978-1-83881-827-2",doi:"10.5772/intechopen.75772",price:119,priceEur:129,priceUsd:155,slug:"advanced-surface-engineering-research",numberOfPages:230,isOpenForSubmission:!1,hash:"4c1a23accacc46fd18b49f2e5c6d303e",bookSignature:"Mohammad Asaduzzaman Chowdhury",publishedDate:"November 14th 2018",coverURL:"https://cdn.intechopen.com/books/images_new/7471.jpg",keywords:null,numberOfDownloads:5811,numberOfWosCitations:9,numberOfCrossrefCitations:9,numberOfDimensionsCitations:14,numberOfTotalCitations:32,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"February 26th 2018",dateEndSecondStepPublish:"March 19th 2018",dateEndThirdStepPublish:"May 18th 2018",dateEndFourthStepPublish:"August 6th 2018",dateEndFifthStepPublish:"October 5th 2018",remainingDaysToSecondStep:"3 years",secondStepPassed:!0,currentStepOfPublishingProcess:5,editedByType:"Edited by",kuFlag:!1,biosketch:null,coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"185329",title:"Prof.",name:"Mohammad Asaduzzaman",middleName:null,surname:"Chowdhury",slug:"mohammad-asaduzzaman-chowdhury",fullName:"Mohammad Asaduzzaman Chowdhury",profilePictureURL:"https://mts.intechopen.com/storage/users/185329/images/system/185329.jpg",biography:"Mohammad Asaduzzaman Chowdhury is a Professor of Mechanical Engineering at Dhaka University of Engineering and Technology (DUET), Gazipur, Bangladesh. His research interests include engineering tribology, surface engineering, coating technology, polymer and composite materials, metals and alloys, erosive wear of different materials, material fabrication, characterization of materials, self–energy-generating materials, and atomic transfer mechanisms. He is an editorial board member for many international journals of repute. Currently, he is working as an editor and reviewer for many ISI and Scopus indexed international journals and books. He has also published many research and review papers in refereed international journals and conference proceedings. Dr. Chowdhury is a consultant, advisor, and expert member of many government and autonomous organizations. He has twenty years of teaching and research experience. His personal interests involve different cultural and social activities as well as writing articles, stories, lyrics, and poems for different newspapers and relevant media.",institutionString:"Dhaka University of Engineering and Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"2",institution:{name:"Dhaka University of Engineering & Technology",institutionURL:null,country:{name:"Bangladesh"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"160",title:"Surface Science",slug:"surface-science"}],chapters:[{id:"62815",title:"Synthesis and Nonlinear Studies on Selected Organic Compounds in Nanostructured Thin Films",slug:"synthesis-and-nonlinear-studies-on-selected-organic-compounds-in-nanostructured-thin-films",totalDownloads:583,totalCrossrefCites:1,authors:[null]},{id:"62411",title:"Shot Peening of Austempered Ductile Iron",slug:"shot-peening-of-austempered-ductile-iron",totalDownloads:514,totalCrossrefCites:0,authors:[null]},{id:"62514",title:"Advanced Electro-Spark Deposition Process on Metallic Alloys",slug:"advanced-electro-spark-deposition-process-on-metallic-alloys",totalDownloads:650,totalCrossrefCites:1,authors:[null]},{id:"62810",title:"Surface Manufacturing of Materials by High Energy Fluxes",slug:"surface-manufacturing-of-materials-by-high-energy-fluxes",totalDownloads:469,totalCrossrefCites:3,authors:[null]},{id:"62869",title:"The Potential of Pyrolytic Biomass as a Sustainable Biofiller for Styrene-Butadiene Rubber",slug:"the-potential-of-pyrolytic-biomass-as-a-sustainable-biofiller-for-styrene-butadiene-rubber",totalDownloads:455,totalCrossrefCites:0,authors:[null]},{id:"62520",title:"Ultrafast Laser Inscription of Buried Waveguides in W-TCP Bioactive Eutectic Glasses",slug:"ultrafast-laser-inscription-of-buried-waveguides-in-w-tcp-bioactive-eutectic-glasses",totalDownloads:455,totalCrossrefCites:0,authors:[null]},{id:"62594",title:"Surface Modification of Fe3O4 as Magnetic Adsorbents for Recovery of Precious Metals",slug:"surface-modification-of-fe3o4-as-magnetic-adsorbents-for-recovery-of-precious-metals",totalDownloads:1060,totalCrossrefCites:2,authors:[null]},{id:"62867",title:"Hidden Resources of Coordinated XPS and DFT Studies",slug:"hidden-resources-of-coordinated-xps-and-dft-studies",totalDownloads:503,totalCrossrefCites:0,authors:[null]},{id:"63360",title:"Efficient Microbial Decontamination of Translucent Liquids and Gases Using Optical Metamaterials",slug:"efficient-microbial-decontamination-of-translucent-liquids-and-gases-using-optical-metamaterials",totalDownloads:566,totalCrossrefCites:0,authors:[null]},{id:"62588",title:"Advanced Surface Treatments for Improving the Biocompatibility of Prosthesis and Medical Implants",slug:"advanced-surface-treatments-for-improving-the-biocompatibility-of-prosthesis-and-medical-implants",totalDownloads:564,totalCrossrefCites:2,authors:[null]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"247041",firstName:"Dolores",lastName:"Kuzelj",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/247041/images/7108_n.jpg",email:"dolores@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"7770",title:"Friction, Lubrication and Wear",subtitle:null,isOpenForSubmission:!1,hash:"9811d708b3a24330f50e319ee70c003f",slug:"friction-lubrication-and-wear",bookSignature:"Mohammad Asaduzzaman Chowdhury",coverURL:"https://cdn.intechopen.com/books/images_new/7770.jpg",editedByType:"Edited by",editors:[{id:"185329",title:"Prof.",name:"Mohammad Asaduzzaman",surname:"Chowdhury",slug:"mohammad-asaduzzaman-chowdhury",fullName:"Mohammad Asaduzzaman Chowdhury"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6671",title:"Paint and Coatings Industry",subtitle:null,isOpenForSubmission:!1,hash:"1dc37c2c972a253d544da9849049222f",slug:"paint-and-coatings-industry",bookSignature:"Faris Yilmaz",coverURL:"https://cdn.intechopen.com/books/images_new/6671.jpg",editedByType:"Edited by",editors:[{id:"36900",title:"Dr.",name:"Faris",surname:"Yılmaz",slug:"faris-yilmaz",fullName:"Faris Yılmaz"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7550",title:"Corrosion Inhibitors",subtitle:null,isOpenForSubmission:!1,hash:"4d09bcd91e393d15a578f1b632f118e7",slug:"corrosion-inhibitors",bookSignature:"Ambrish Singh",coverURL:"https://cdn.intechopen.com/books/images_new/7550.jpg",editedByType:"Edited by",editors:[{id:"215348",title:"Dr.",name:"Ambrish",surname:"Singh",slug:"ambrish-singh",fullName:"Ambrish Singh"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7253",title:"Coatings and Thin-Film Technologies",subtitle:null,isOpenForSubmission:!1,hash:"98b8dfac28575877f1846a661c9150bc",slug:"coatings-and-thin-film-technologies",bookSignature:"Jaime Andres Perez-Taborda and Alba G. Avila Bernal",coverURL:"https://cdn.intechopen.com/books/images_new/7253.jpg",editedByType:"Edited by",editors:[{id:"193020",title:"Dr.",name:"Jaime Andres",surname:"Perez Taborda",slug:"jaime-andres-perez-taborda",fullName:"Jaime Andres Perez Taborda"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10061",title:"21st Century Surface Science",subtitle:"a Handbook",isOpenForSubmission:!1,hash:"69253b3c7ba801a5fcd9c47827345f93",slug:"21st-century-surface-science-a-handbook",bookSignature:"Phuong Pham, Pratibha Goel, Samir Kumar and Kavita Yadav",coverURL:"https://cdn.intechopen.com/books/images_new/10061.jpg",editedByType:"Edited by",editors:[{id:"236073",title:"Dr.",name:"Phuong",surname:"Pham",slug:"phuong-pham",fullName:"Phuong Pham"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10050",title:"Corrosion",subtitle:null,isOpenForSubmission:!1,hash:"cf66006063d4d72349fb33cc056095c1",slug:"corrosion",bookSignature:"Ambrish Singh",coverURL:"https://cdn.intechopen.com/books/images_new/10050.jpg",editedByType:"Edited by",editors:[{id:"215348",title:"Dr.",name:"Ambrish",surname:"Singh",slug:"ambrish-singh",fullName:"Ambrish Singh"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7343",title:"Superhydrophobic Surfaces",subtitle:"Fabrications to Practical Applications",isOpenForSubmission:!1,hash:"017db4d856b5d454aead24128743ba3e",slug:"superhydrophobic-surfaces-fabrications-to-practical-applications",bookSignature:"Mehdi Khodaei, Xiuyong Chen and Hua Li",coverURL:"https://cdn.intechopen.com/books/images_new/7343.jpg",editedByType:"Edited by",editors:[{id:"19478",title:"Dr.",name:"Mehdi",surname:"Khodaei",slug:"mehdi-khodaei",fullName:"Mehdi Khodaei"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8242",title:"Applied Surface Science",subtitle:null,isOpenForSubmission:!1,hash:"b2515a9d613325af2ddf6d8ef2b53f4d",slug:"applied-surface-science",bookSignature:"Gurrappa Injeti",coverURL:"https://cdn.intechopen.com/books/images_new/8242.jpg",editedByType:"Edited by",editors:[{id:"12369",title:"Dr.",name:"Gurrappa",surname:"Injeti",slug:"gurrappa-injeti",fullName:"Gurrappa Injeti"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"43498",title:"Treatment of Coronary Artery Bypass Graft Failure",doi:"10.5772/54928",slug:"treatment-of-coronary-artery-bypass-graft-failure",body:'
The concept of surgical revascularization for coronary artery disease (CAD) originated in the early 20th century. A pioneer in this field is Beck, a surgeon who in 1935 developed an indirect technique of myocardial revascularization by grafting a flap of the pectoralis muscle over the exposed epicardium to create new blood supply. [1] Later, Beck also developed another revascularization technique by anastomosis between the aorta and the coronary sinus. [2] In 1946, the Vineberg procedure was introduced in which the internal mammary artery (IMA) was used to implant directly into the left ventricular and is hence considered the forerunner of coronary artery bypass grafting (CABG). This technique was the first intervention documented to increase myocardial perfusion and was successfully performed in over 5,000 patients between 1950 till 1970. [3-5] The major breakthrough in surgery, however, was the invention of the heart-lung machine in 1953, which allowed surgeons to perform open-heart procedures on a non-beating heart and controlled operating field while protecting other vital organs. [6] Still it was not until 1960 when the first successful human coronary artery bypass surgery was performed by Goetz and Rohman, who used the IMA as the donor vessel for anastomosis to the right coronary artery. [7] The bypass graft technique as we know today was developed by Favaloro in 1967. [8] In his physiologic approach in the surgical management of coronary artery disease, Favaloro and his team initially used a saphenous vein autograft to bypass a stenosis of the right coronary artery. Shortly hereafter, Favaloro began to use the saphenous vein as a bypassing conduit. After the saphenous vein bypass procedure was extended to include the left arterial system by Johnson [9], the use of the IMA for bypass grafting was performed by Bailey and Hirose in 1968. [10] Arguably, the first successful IMA – coronary artery anastomosis was already performed 4 years earlier by the Russian surgeon Vasilii Kolesov. [11] Use of the radial artery (RA) as a bypass conduit was introduced by Carpentier in 1971 and fell into disrepute shortly after its introduction because of high failure rates but was revisited as many of these original grafts appeared widely patent at 6 years. [12,13] Initially used as a free graft in a fashion similar to that of the saphenous vein graft, more recently the RA has been used as a T or Y graft from the left IMA (LIMA) or an extension graft from the distal right IMA (RIMA). On the basis of superior long-term outcomes of arterial conduits compared with vein grafts, other arteries have been used in CABG such as the gastroepiploic artery (GEA), the inferior epigastric artery (IEA), the splenic artery, the subscapular artery, the inferior mesenteric artery, the descending branch of the lateral femoral circumflex artery, and the ulnar artery. However none of these arteries have shown similar patency rates as the internal mammary artery.
Surgical revascularization in the current era - A number of studies and trials have consistently shown the benefit of CABG in select patient populations. Indisputable, surgical revascularization which in most cases is performed utilizing the saphenous vein for bypassing non LAD-lesions and arterial bypass grafts for LAD lesions, has dramatically changed the management of patients with ischemic heart disease. Currently, over 300,000 patients undergo CABG in the United States each year. [14] Although the short-term outcomes of CABG are generally excellent, patients remain at risk for future cardiac events due to progression of native coronary disease and/or coronary bypass graft failure. [15-18] To illustrate, over half of saphenous vein grafts (SVG) are occluded at 10 years post CABG and an additional 25% show significant stenosis at angiographic follow-up. [19] Additionally, diseased grafts represent an increasing proportion of culprit lesions and acute graft occlusion may cause acute coronary syndromes (ACS). [20] In the next paragraphs we will describe in further detail the pathophysiologic mechanisms that lead to coronary artery bypass graft failure, and elude to management strategies.
The use of the SVG, arterial grafts or both during CABG is largely depending on the site of anatomic obstruction, the availability of good quality conduits, patient preferences, and the clinical condition of the patient. Adequate arterial conduits are not always available, in contrast SVG are usually of good quality and calibre and are easily harvested, and are thus commonly used as conduits. However, there is an increasing interest for the use of arterial conduits as coronary artery bypass grafts, especially for bypassing the left coronary artery. Although, the choice to use arterial conduits partly depends on the coronary run-off, the long-term patency of arterial grafts is superior for CABG compared to SVG. As more than half of SVG are occluded at 10 years post CABG and an additional 25% show significant stenosis at angiographic follow-up. [19] SVG failure is the main cause of repeat intervention either by redo CABG or PCI and is even more common than the progression of native coronary artery disease in patients whom underwent CABG. In spite the fact that SVG failure remains a significant clinical and economic burden, the majority of CABG procedures continue to use SVG. [21]
The concept of the ‘failing graft’ is one of a patent graft whose patency is threatened by a hemodynamically significant lesion in the inflow or outflow tracts or within the body of the graft. Salvage of the failing and failed bypass graft remains an important clinical and technical challenge. The high incidence of graft failure has led to the evolution of graft surveillance programs to detect ‘failing’ grafts and research has focussed on means to control the development of intimal hyperplasia. [22]
The saphenous vein consists of three layers: the intima, media, and adventitia. The intima is composed of a continuous layer of endothelial cells on the luminal surface of the vessel. Beneath lies the fenestrated basement membrane embedded with a fragmented internal elastic lamina. The media comprises of smooth muscle cells (SMC) arranged in an inner longitudinal and an outer circumferential pattern with loose connective tissue and elastic fibers interlaced. The middle muscle layer is most extensive at the insertion points of the valves and leaflets. The adventitia forms the outer layer and consists of longitudinally arranged SMC, collagen fibers and a network of elastin fibers, in addition to vascular and nerve supplies to the vessel.The great saphenous vein is the most frequently used conduit for myocardial revascularization but other venous conduits such the short saphenous vein or upper extremity veins (cephalic and basilica) can be used as well.
Studies of saphenous veins harvested for bypass procedures have shown that many have abnormal histological and physical attributes. [23,24] Moreover, the quality of the saphenous vein can have significant clinical consequences. Therefore, vein grafts in the arterial circulation must be considered as a viable, constantly adapting and evolving conduit.
Several intrinsic and extrinsic factors may play a role in the mechanism of SVG failure. At the time of harvest, the quality of the saphenous veins may be poor, demonstrating a spectrum of pre-existing pathological conditions ranging from significantly thickened walls to post phlebitic changes and varicosities. Between 2% and 5% of saphenous veins are unusable and up to 12% can be considered diseased which reduce the patency rate by one half compared to non-diseased veins. [25] In addition, the inevitable vascular trauma that occurs during SVG harvesting itself can also lead to damage to the endothelium and SMC and thereby contribute to graft failure. Surgical manipulation and high-pressure distension to reverse spasm during harvesting leads to loss of endothelial integrity and the antithrombogenic attributes of the endothelium, rendering the SVG prone to subsequent occlusive intimal hyperplasia and/or thrombus formation. [26] During harvesting the vasa vasorum and nervous network of the SVG are devided, making the graft dependent on diffusion for weeks until adequate circulation is esthablished. [27-32] Ischemic insult and decreased production of nitric oxide and adenosine may cause SMC proliferation. [33] As it has been demonstrated that intimal hyperplasia does not occur in vein-to-vein isografts, it can be stated that pathologic changes seen in SVG in the arterial circulation are predominantly caused by hemodynamic and physiochemical changes. [34]
SVG failure can be divided into three temporal categories: early (0 to 30 days), midterm (30 days to 1 year) or late (after 1 year). Early SVG failure due to thrombotic complications is mainly attributable to technical errors during harvesting, anastomosis or comprised anatomic runoff. [19,35-37] It occurs in 15% to 18% of VG during the 1st month. [38-40] Early thrombotic complications in SVG in the arterial circulation are caused by a reduction of tissue plasminogen activator, attenuation of thrombomudulin and reduced expression of heparin sulphate. [41]
Midterm SVG failure is mainly caused by fibrointimal hyperplasia as it serves as the foundation for subsequent graft atheroma leading to occlusive stenosis. The release of a variety of mediators, growth factors, and cytokines by the injured endothelium, platelets and activated macrophages will cause migration and proliferation of SMC. Diminished production of endothelial nitric oxide (NO), prostaglandin 12 and adenosine will further contribute to and enhanced SMC proliferation, leading to development of neointimal hyperplasia. [19,33,37,42-44] Changes in the flow pattern within the vessel (shear stress) an ischemic insults may contribute to changes in the SVG at this stage. SVG are exposed to much higher mechanical pressure that they were adapted to (arterial versus venous blood pressure) which can potentially stimulate SMC proliferation. Moreover, after encountering arterial flow patterns increased levels of intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and monocyte chemotactic protein-1 will facilitate leukocyte-endothelial interactions so that leukocyte infiltration of the lesions will ensue. [34] Finally, the adaptive response to hemodynamic factors, i.e. wall shear stress, may affect the distal site of the anastomosis leading to SVG failure. [45,46] Midterm SVG failure accounts for an additional 15% to 30%. [47,48] In the course of vessel remodelling, late SVG failure is characterized by progression of intimal fibrosis at the cost of a reduction in cellularity which may contribute to progression of SMC apoptosis. [19,34,41,44] In addition, perivascular fibroblasts may also be involved in neointimal formation and matrix deposition as these cells may exhibit contractile elements while migrating from the adventitia towards the media. [49] After 1 year most SVG stenosis is due to atherosclerosis but although vein graft atherosclerosis is accelerated compared to arteries, evidence show that a fully evolved plaque appear after 3 to 5 years of implantation. [35,47,50] In SVG there is no focal compensatory enlargement in the stenotic segments which is in contrast to native atherosclerotic arteries in which the development of an atherosclerotic plaque is associated with enlargement of the vessel and preservation of the lumen area until plaque progression exceeds the compensatory mechanism of the vessel. [51] Several studies show that SVG patency at 10 years is no more than 50% to 60%. [19,41,52,53] Finally, several studies have suggested a role of immune cells in neointimal formation as macrophages are found in the intima, while T-lymphocytes are present in the adventitia of neointimal lesions wit a predominance of CD4+ cells. [54-56]
In a later stage atherosclerotic lesions may be complicated by aneurysmal dilatation which is found to correlate with thrombosed SVG. (66) The occurrence of atheroembolism form the diseased graft or plaque rupture may cause late thrombosis necessitating revascularization therapy. [57,58] In general, SVG thrombosis is the major cause of morbidity and mortality. [19,41]
Predictors of graft patency 3 years after CABG were evaluated by Veterans Affairs Cooperative Study Group. [59] Multivariable analysis showed that the only factors that were predictive were vein preservation solution temperature ≤5ºC, serum cholesterol, the number of proximal anastomoses ≤2, and recipient artery diameter >5 mm. Thus, predictors of 3-year graft patency are most closely related to operative techniques and the underlying disease. In another study, factors that predict the late progression of SVG atherosclerosis were evaluated in 1248 patients in the Post-CABG trial. [47] Factors independently associated with the progression of disease were maximum stenosis of the graft at baseline angiography, years after CABG, moderate therapy to lower LDL cholesterol, prior MI, high triglyceride levels, small minimum graft diameter, low HDL concentration, high LDL concentration, high mean arterial pressure, low left ventricular ejection fraction, male gender, and current cigarette smoking. Finally, concerns have been raised about the possibility of worse outcomes when a SVG is used for multiple distal anastomosis compared to single anastomosis. In a substudy of the PREVENT IV trial, the use of SVG conduits with multiple distal anastomoses was associated with a significantly higher rate of ≥75 percent stenosis of the SVG on angiography at one year. [60] Moreover, clinical follow-up showed a trend towards a higher rate of the adjusted composite of death, MI, or revascularization at five years.
Noteworthy, the clinical impact of SVG failure is still debated. Not all grafts that have angiographic stenosis or occlusion will cause symptoms, and probably a substantial of SVG that fail do not impact outcomes.
Several arterial conduits are suitable for myocardial revascularization and the arterial conduits can be divided into 3 types according to functional class (Table 1). Type I arterial grafts are the somatic arteries including the IMA, IEA, and subscapular artery. Type II arterial grafts are the splanchnic arteries including the GEA, splenic artery, and inferior mesenteric artery. Type III arterial grafts are the limb arteries including the RA, ulnar artery, and lateral femoral circumflex artery. Compared to functional class type II and III, type I is less spastic. [61] Although the full length of arterial grafts is reactive, the major muscular components are located at the two ends of the artery (muscular regulator). [62] Therefore, in terms of preventing vasospasm of arterial grafts, trimming off the small and highly reactive distal end of the grafts (IMA, GEA, IEA, or other grafts) may be important and clinically feasible.
Type I - Somatic arteries | \n\t\t\tLess spastic | \n\t\t\tInternal mammary artery | \n\t\t
\n\t\t\t | \n\t\t\t | Inferior epigastric artery | \n\t\t
\n\t\t\t | \n\t\t\t | Subscapular artery | \n\t\t
Type II - Splanchnic arteries | \n\t\t\tSpastic | \n\t\t\tGastroepiploic artery | \n\t\t
\n\t\t\t | \n\t\t\t | Splenic artery | \n\t\t
\n\t\t\t | \n\t\t\t | Inferior mesenteric artery | \n\t\t
Type III - Limb arteries | \n\t\t\tSpastic | \n\t\t\tRadial artery | \n\t\t
\n\t\t\t | \n\t\t\t | Ulnar artery | \n\t\t
\n\t\t\t | \n\t\t\t | Lateral femoral circumflex artery | \n\t\t
Functional classification of arterial grafts according to physiological and pharmacological contractility, anatomical, and embryological characteristic
Studies have demonstrated that there are differences between arterial and venous grafts: 1) arterial grafts are less susceptible to vasoactive substances then veins [63]; 2) the arterial wall is supplied by the vaso vasorum and in addition through the lumen, whereas the veins are only supplied by the vaso vasorum [64]; 3) the endothelium of the arteries may secrete more endothelium-derived relaxing factor [65]; 4) the structure of the artery is subject to high pressure, whereas the vein is subjected to low pressure. While the SVG have to adapt to the high pressure, the arterial grafts do not which may partly explain the difference in the long-term outcome.
Similar like SVG, the arterial grafts can also be divided into three layers: the intima, media, and adventitia. As a result of location at different parts of the body and supply to different organs, differences in gross anatomy among arterial grafts have been observed. Divergent anatomic structures of the arteries have been observed. One of the most obvious differences is that arteries such as the GEA, IEA, and RA contain more smooth muscle cells in their walls and are therefore less elastic compared to other arteries such as the IMA which may be more elastic because they contain more elastic laminae. [64] Such structure divergence may also explain the difference in phsysiologic and pharmacologic reactivity.
The need for repeat revascularization is substantially reduced with the use of arterial conduits, since long-term patency is much higher compared to SVG. [66-68] In contrast to SVG, arterial grafts appear to be more resistant to the influence of atherogenic factors and incur only minor traumatic and ischemic lesions, since they are not removed from the blood circulation but are prepared locally, with few ligations and preservation of blood flow. [69] Since 1986, the LIMA has been used in more than 90% of CABG procedures. Less frequently, the RIMA is used. The early patency of a LIMA anastomosed to the left anterior descending (LAD) is reported to be almost 99%. [70] The mean patency of LIMA to coronary conduit at 5 years is reported 98%, at 10 years it is 95%, and at 15 years it is 88%. [71] Differences are observed between territory grafted, the 10 year LIMA patency to the LAD is reported to be 96% and to the circumflex (Cx) 89%. [72] The early patency of the RIMA anastomosed to major branches of the left circumflex artery is approximately 94%. [70] The mean RIMA patency at 5 years is reported to be 96%, at 10 years it is 81% and at 15 years it is 65%. [71] Again differences are observed, the RIMA graft patency to the LAD artery is 95% at 10 years and 90% at 15 years. Ten-year RIMA patency to the Cx marginal is 91%, right coronary artery is 84%, and posterior descending artery is 86%. [72] In situ RITA and free RITA had similar ten-year patency, 89% vs 91% respectively. RA patency is reported to range between 83% to 98% at 1 to 20 years but lower rates have been reported. [73] The patency rate estimated by the Kaplan-Meier method for the GEA conduit was 96.6% at 1 month, 91.4% at 1 year, 80.5% at 5 years, and 62.5% at 10 years. [74] Arterial grafts are not uniform in their biological characteristics and difference in the perioperative behaviour and in the long-term patency may be related to different characteristics. It should be taken into account in the use of arterial grafts that some grafts need more active pharmacological intervention during and after operation to obtain satisfactory results.
Although, the IMA is the most used conduit to restore the blood flow to the LAD, it is less easy to use because of its complicated preparation and postoperative complications. Specific reasons for not to use the RIMA may include additional time to harvest, concerns over deep sternal wound infection, myocardial hypoperfusion, and unfamiliarity. Besides the potentially deleterious effect on the vascular supply of the forearm and hand, potential spasm and size matching to target coronary artery are the main drawback for the use of RA in CABG. [75,76]
Although all arterial grafts may develop vasospasm, it develops more frequently in the GEA and RA, than the IMA and IEA. [13,77] Two types of vasoconstrictors are found to be important spasmogens in arterial grafts. [78] Type I vasoconstrictors are the most potent and they strongly contracts arterial grafts even when the endothelium is intact. The constrictors are endothelin, prostanoids such as thromboxane A2 and prostaglandin F2α, and alpha1-adrenoceptor agonists. Type II vasoconstrictors induce only weak vasoconstriction when the endothelium is intact, but play an important role in the spasm of arterial grafts when the endothelium is destroyed by surgical manipulation. Type II vasoconstrictor is 5-hydroxytryptamine.
Early IMA graft failure is attributed to technical errors and distal anastomosis. [79,80] Nontechnical factors that may affect the patency of the arterial graft are high levels of LDL cholesterol and triglycerides, and high levels of lipoprotein(a), a thrombogenic molecule that is related to the hypercoagulable state. Other classical risk factors for coronary artery disease, such as diabetes mellitus, smoking and hypertension may also affect the patency of the arterial graft. Age may be of influence the quality of the arterial graft.
Furthermore, competitive flow and low-flow profoundly affect graft patency. Low-grade graft stenoses in the target artery proximally are a major cause of competitive flow which may lead to a decrease in antegrade flow in the arterial graft causing early failure (‘disuse athrophy’). The SVG and IMA are more tolerant than the RA and GEA conduits. This is likely to be related to biological differences as the RA and GEA have a thick layer of smooth muscle or poor endothelial function in these muscular conduits. Therefore, it is recommended to avoid grafting target arteries with a stenosis less than 90% with RA grafts. [81]
Atherosclerosis in arterial grafts can develop before coronary grafting when the graft is in the in situ native position, or after. The incidence of atherosclerosis in native arteries in the in situ position in the four major arterial grafts is low, especially in the IMA. [64] The incidence of atherosclerosis in bypass grafts is also low, in IMA grafts even as late 15 to 21 years after CABG. [67,82] However, the degree of stenosis in the native vessel is a major predictor of IMA graft patency. The observed association between non-significant stenosis of the native artery and high occlusion rate of the arterial bypass conduit raises concerns about the use of IMA in the treatment of native vessels with only mild or moderate stenosis. [83] In addition, the target vessel for the IEA must be one that is completely occluded or severely stenotic, with low coronary resistance, and in territories not totally infarcted to avoid “string sign” (conduit <1 mm diameter). Although the incidence of atherosclerosis is low in arterial grafts, 2 other morphologic changes may be present in arterial graft, fibrointimal proliferation and fibrosis representing organized thrombus. [84] The presence of fibrointimal proliferation is associated with long-term IMA graft narrowing and may be an important factor for late graft failure. Despite hypertension was associated with increased fibrointimal proliferation in SVG, this correlation could not be found in IMA grafts. [84]
Following graft revascularization, patients remain at very high risk for subsequent clinical events. In a large study from the Duke Cardiovascular Databank, patients who underwent catheterization 1 to 18 months after their first CABG were evaluated. [85] Patients were classified on the basis of their worst SVG stenosis as having no (<25%), noncritical (25% to 74%), critical (75% to 99%), or occlusive (100%) SVG disease and the primary outcome measure was the composite of death, MI or repeat revascularization. At 10-years, the corresponding adjusted composite event rates were 41.2%, 56.2%, 81.2%, and 67.1%, respectively (p<0.0001) and most events occurred immediately after catheterization in patients with critical and occlusive SVG disease. Multivariate analysis revealed critical, non-occlusive SVG disease as the strongest predictor of composite outcome (hazard ratio 2.36, 95% CI [2.00-2.79], p<0.0001).
Many patients with recurrent stable angina following CABG can be treated medically for their symptoms and risk factor reduction. Evaluation for ischemia is as in other patients with stable angina without prior CABG. However, early diagnostic angiography is suggested as the different anatomic possibilities, i.e. graft stenosis or progression of native vessel disease in nonbypassed vessels can lead to recurrent ischemia. In patients with recurrent angina, ACS, change in exercise tolerance, positive exercise test after CABG, an increased risk for coronary events is observed. [86-88]
In all patients with coronary heart disease aggressive risk factor reduction is recommended which includes aspirin, treatment for hypertension and serum lipids, avoidance of smoking, and controlling serum glucose in diabetic patients. The bypass angioplasty revascularization investigation (BARI) trial illustrated that intensive risk-factor modification and hypolipid medication use slows atherosclerosis progression within native coronary arteries of CABG-treated patients and may to a lesser extent improve long-term patency of surgical conduits. [89]
Antiplatelet therapy - Antiplatelet therapy is recommended following CABG since it improves SVG patency and clinical outcomes. The 2008 EACTS guideline on antiplatelet and anticoagulation management in cardiac surgery [90] recommends that aspirin should be given postoperatively to all patients without contra-indications after CABG in order to improve the long-term patency of SVG. The recommended dose given is 150—325 mg. Several studies have shown a trend towards maximal benefit with 325 mg/day in the first year. [91-95] In contrast, there is no evidence that the use of aspirin after coronary artery bypass grafting improved the patency of arterial grafts. However, aspirin may be recommended on the basis of improved survival of patients in general who have atherosclerotic disease.
The optimal timing of the first dose of aspirin for patients after CABG was investigated in a meta-analysis of 12 studies and found that the benefit of aspirin was optimal if started at 6 h after surgery. [96] Although, the largest risk reduction was observed when aspirin was given at 1 h after operation, there was a non-significant increase in the rate of re-operation in this group. [91] In contrast, there was no benefit found in giving aspirin if starting more than 48 h postoperatively. [97] Practically, Aspirin should be commenced within 24 h of CABG.
Whether clopidogrel given in addition of aspirin to high-risk patients after CABG would reduce thrombotic complications was evaluated in several studies. Registry data showed that adding clopidogrel to aspirin was independently associated with a decrease in recurrence of anginal complaints and adverse cardiac events following off-pump CABG. Nonetheless, clopidogrel use beyond 30 days did not show a significant effect on adverse cardiac events. [98] In the randomized CASCADE (Clopidogrel After Surgery for Coronary Artery Disease) study, aspirin monotherapy was compared with aspirin plus clopidogrel in 113 patients undergoing CABG and SVG intimal hyperplasia was determined by intravascular ultrasound at 1 year. [99] Compared with aspirin monotherapy, the combination of aspirin plus clopidogrel did not significantly reduce SVG intimal hyperplasia 1 year after CABG. Although the study was not powered for clinical outcomes, there was no significant difference in SVG patency or cardiovascular events, neither was there a difference in the incidence of major bleeding between the 2 treatment groups at 1 year. Moreover, the superiority of clopidogrel over aspirin for optimising graft patency after CABG has not been established and thus aspirin should be regarded as the drug of first choice, however, clopidogrel is an acceptable alternative to aspirin. [90]
In patients whom underwent CABG for ACS subgroup analyses of the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events) and CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) study provides supportive evidence to prescribe clopidogrel for 9 to 12 months in addition to aspirin. [100,101] In patients undergoing coronary bypass surgery with a coronary stent in situ implanted within 1 year, clopidogrel should be continued if the stented vessel has not been grafted. Finally, in patients with SVG failure treated with PCI, prehospital use of antiplatelet therapy compared with patients not using antiplatelets was associated with lower occurrence of major adverse cardiac events after SVG intervention. [102] Also, DAPT did not improved outcomes when compared to single antiplatelet therapy.
Warfarin – Conflicting evidence is reported whether warfarin in addition to aspirin is beneficial in patients post CABG. In an extended follow-up of 7.5 years of the post CABG trial, low-dose anticoagulation compared with placebo reduced the rate of death by 35%, deaths or myocardial infarction (MI) by 31%, and the composite clinical endpoint of death, MI, stroke, CABG, or angioplasty by 17%. [103] However, in a smaller randomized trial, moderate-intensity oral anticoagulation alone or combined with low-dose aspirin was not superior to low-dose aspirin in the prevention of recurrent ischemic events in patients with non-ST-elevation ACS and previous CABG. [104] Currently, the American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines recommended that oral anticoagulation in addition to aspirin can be considered only when it is indicated for other reasons. [105]
Lipid lowering therapy – Clinical trials have shown that lipid lowering therapy (in particular statins) is beneficial in patients who have undergone CABG. [103,106-110] Besides the lipid lowering effect, statins also exert a number of pleiotropic effects on the vascular wall which may effect SVG in a similar way. In SVG, statins have shown to reduce vascular oxidative stress, improve NO bioavailability and reduce vascular inflammation, all critical components of SVG failure. [111] Subsequently, statins have systemic antithrombotic and anti-inflammatory effects and their administration may prevent acute SVG failure post CABG. [112] Aggressive lipid lowering therapy may be beneficial for long-term patency of grafts. In the randomized Post CABG trial, patients who had undergone bypass surgery 1 to 11 years before base line with elevated serum LDL-cholesterol concentrations (130 to 175 mg/dL / 3.4 to 4.5 mmol/L) were assigned to receive either aggressive lipid lowering therapy with lovastatin and, if needed, cholestyramine (target LDL-cholesterol <100 mg/dL / 2.6 mmol/L) or to moderate therapy (target LDL-cholesterol of approximately 134 mg/dL / 3.5 mmol/L). [106] Compared to a moderate strategy, aggressive lipid lowering therapy was associated with a delay in the progression of graft disease at an average of 4.3 years as assessed by angiography. Moreover, after clinical follow-up of 7.5 years, a 30% reduction in revascularization procedures and a 24% reduction in the composite endpoint of cardiovascular death, MI, stroke, CABG, or angioplasty were seen. [103] Similar findings were observed in a post hoc analysis from the TNT trial. In patients with previous CABG, simvastatine 80 mg compared to simvastatine 10 mg, was significantly more effective in reducing the rate of a combined cardiovascular endpoint at a median follow-up of 4.9 years (9.7% versus 13.0%). [110] Repeat revascularization with either CABG or PCI was also significantly reduced in patients assigned to the higher dose (11.3% versus 15.9%).
Antiplatelet agents and statin therapy are the only modalities with proven efficacy for the prevention of SVG stenosis. The routine use of beta blockers, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, or nitrates post CABG is not supported by data, however, many of these patients require beta blockers and ACE inhibitors for preexistent heart failure or MI according to the ACC/AHA guideline recommendations. [113,114]
The PREVENT IV trial, including almost 3,000 patients that underwent CABG, demonstrated that rates of use of secondary prevention medications in patients with ideal indications for these therapies are high for antiplatelet agents and lipid-lowering therapy, but suboptimal for beta-blockers and ACE inhibitors or ARBs. [115] The study demonstrated that the use of multiple secondary prevention medications after CABG was associated with significant improve in clinical outcome death or MI at 2 years (4.2% in patients taking all indicated medications versus 9.0% in patients taking half or fewer of the indicated medications). No association was found between the use of most individual medications and subsequent outcomes, thus underscoring the importance of ensuring appropriate secondary prevention measures after CABG.
In the European Society of Cardiology (ESC)/ European Association for Cardio-Thoracic Surgery (EACTS) guidelines on myocardial revascularization [116] published in 2010 states that in acute post-operative graft failure PCI may be an alternative to re-operation with acceptable results and fewer complications. [117] The target for PCI is the body of the coronary artery of the arterial graft while freshly occluded SVG or the anastomosis itself should be targeted due to the risk of embolization or perforation. When multiple grafts are occluded or the graft or native coronary artery appears unsuitable for PCI, surgery should be favoured. In asymptomatic patients, redo CABG or PCI should only be considered if the graft or coronary artery is of good size, severely narrowed and supplies a large territory of myocardium. Redo CABG or PCI should be decided by the Heart Team.
Repeat revascularization in patients with late graft failure is indicated in the presence of severe anginal symptoms despite anti-anginal medication. In patients with mild or no symptoms repeat revascularization is dependent on risk stratification by non-invasive testing. [118,119] In patients with previous CABG, PCI has worse acute and long-term outcomes than in patients without prior CABG. Redo CABG has a two- to four-fold higher mortality than the first procedure which is mainly driven by comorbidity and less by the re-operation itself. [120,121] There is limited data comparing the efficacy of PCI with redo CABG in patients with previous CABG. In a propensity analysis of long-term survival after redo CABG or PCI in patients with multivessel disease and high-risk features, short-term outcome was very favourable, with nearly identical survival at 1 and 5 years. [118] However, in the AWESOME RCT and registry the overall in-hospital mortality was higher in the redo CABG group compared to the PCI group. [17,122] Because of the initial higher mortality of redo CABG and comparable long-term mortality, the guidelines state that PCI is the preferred revascularization strategy in patients with LIMA or amenable anatomy. Redo CABG is preferred in patients with more diseased or occluded grafts, reduced systolic function, total occlusions of native coronary arteries or in the absence of a patent arterial graft. [118] If possible, the IMA is the conduit of choice when performing redo CABG. [123]
In the 2012 appropriateness criteria for coronary revascularization focussed update of the American College of Cardiology Foundation Appropriateness Criteria Task Force (ACCF), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Thoracic Surgeons (STS), American Association for Thoracic Surgery (AATS), American Heart Association (AHA), and the American Society of Nuclear Cardiology (ASNC) it is stated that in patients with prior CABG, the presence of high-risk findings on noninvasive testing, higher severity of symptoms, or an increasing burden of disease in either the bypass grafts or native coronaries tended to increase the likelihood of an appropriate rating. [119] In patients with prior CABG receiving no or minimal anti-ischemic therapy or having low-risk findings on non-invasive testing revascularization was considered inappropriate. No specific recommendations are provided on the strategy for revascularization, performing redo CABG or PCI.
Both the ESC/EACTS guidelines on myocardial revascularization and the ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update do not provide recommendations for patients with prior CABG presenting with (non) ST segment elevation myocardial infarction (STEMI) or ACS.
Implantation of coronary stents has become the preferred revascularization strategy for treatment of graft lesions, because redo CABG is associated with an increased morbidity and mortality. [17,124-129] Compared to native vessel stenting, stenting of graft lesions is associated with higher rates of periprocedural events as well as cardiac events at follow-up, due to distal embolization and subsequent no-reflow and higher percentages of restenosis. [124,125,130,131] This increased risk is mainly attributed to the friable, degenerated atheromatous and thrombotic debris that develop when SVGs deteriorate. [132] Moreover, patients with graft intervention often have a higher generalized atherosclerotic burden and more comorbidities. [130,131] To date, SVG graft intervention accounts approximately for 5% to 10% of all PCI.
Early graft failure - The incidence of early graft failure within 24 h after CABG is about 1% to 3%. [133] Perioperative graft failure following CABG may result in acute myocardial ischemia which may necessitate acute secondary revascularization procedure to salvage myocardium, preserve left ventricular function and improve patient outcome. Perioperative MI and rise in cardiac markers after CABG is associated with a substantially increased in-hospital morbidity and mortality. [134-136] The most common graft-related causes of myocardial ischemia after CABG are graft occlusion due to acute graft thrombosis, graft kinking or overstretching, postoperative graft spasm and subtotal or hemodynamic relevant anastomotic stenosis. [137,138] Nongraft-related causes for myocardial ischemia after CABG are surgery-related possibly due to surgical manipulation on pre-existing microembolizing and disintegrating unstable plaque and include inadequate cardioplegic perfusion and myocardial protection, incomplete revascularization, or distal coronary microembolization. [139-141] Rapid identification of early graft failure after CABG and diagnostic discrimination from other causes enables an adequate reintervention strategy for re-revascularization, i.e. redo CABG or PCI, and may prevent irreversible myocardial ischemia. Thus far, limited non-randomized data is available showing that in patients with acute perioperative myocardial ischemia due to early graft failure following CABG, emergency PCI may limit the extent of myocardial cellular damage compared with redo CABG. [133] A nonsignifiant numerical difference was observed in in-hospital and 1-year mortality between the PCI group or redo CABG (12.0% and 20.0% in PCI group versus 20.0% and 27% in redo CABG group). Moreover, compared to acute redo-CABG, emergency PCI is quicker and less invasive. Importantly, in this study patent grafts were observed in 25% to 34% of the patients, therefore repeat coronary angiography should be applied when myocardial ischemia due to acute graft failure is suspected. Regarding the type of bypass graft, LIMA graft failure may be responsible for acute ischemic complications after CABG in at least a third up to half of the cases. [133,138,142]
Recurrent angina during the early postoperative period is usually due to a technical problem with a graft or with early graft closure and there is an indication for prompt coronary angiography with percutaneous revascularization. The feasibility of PCI in patients presenting with clinical evidence of ischemia within 90 days of CABG was evaluated in 2 registries. Most patients presented with ACS and the most common cause of graft failure was occlusion or thrombosis. Both registries showed that patients with graft failure can undergo PCI with a relatively low risk for in-hospital mortality or nonfatal major complications. [143,144]
SVG failure - Recurrent angina after the first few months after CABG is caused by both graft disease and by progression of atherosclerosis in non-bypassed vessels. Percutaneous intervention in SVG lesions was evaluated in several randomized studies. The SAVED (Saphenous Vein de Novo) study randomized 200 patients with SVG lesions to placement of Palmaz-Schatz bare metal stent (BMS) or standard balloon angioplasty (BA) and demonstrated that compared to BA, bare metal stents (BMS) were associated with a higher procedural success (92% vs. 69%, p<0.001) but they had more frequent hemorrhagic complications (17% vs. 5 %, p<0.01). [145] At 6 months, a non-significant reduction in angiographic restenosis was observed (36% vs. 47%, p=0.11) and clinical follow-up at 9 months showed that freedom from death, MI, repeated bypass surgery, or revascularization of the target lesion was significantly better in the stent group (73% vs. 58 %, P = 0.03). Based on the results of the SAVED study, the majority of patients with SVG stenosis are treated with stenting. To prevent distal embolization form friable atheroemboli, and in addition may serve as a smooth-muscle cell barrier to decrease restenosis, stents covered with a mesh, most commonly polytetrafluorethylene (PTFE), were evaluated. However, 3 prospective randomized trails have not shown benefit with covered stents with respect to major adverse cardiac events nor in preventing restenosis. [146-148]
In native coronary arteries, drug-eluting stents (DES) have demonstrated a marked reduction in in-stent restenosis compared to BMS in the treatment of coronary artery disease. Several DES with different stent platforms, polymers or drugs are available. In the RRISC (Reduction of Restenosis in Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent) trial, 75 patients were randomized to sirolimus-eluting stent (SES) or BMS. [149] At 6 months follow-up, in-stent late loss was significantly reduced in SES (0.38 ± 0.51 mm vs. 0.79 ± 0.66 mm in BMS). Target lesion revascularization rate was also significantly reduced (5.3% vs. 21.6%) but no difference in death and MI was observed. Howbeit, a post hoc analysis of RRISC trial at 3 years reported similar rates of target vessel revascularization and while statistically underpowered for clinical outcomes, significantly higher all-cause mortality was reported with SES compared with BMS. [150] The SOS (Stenting of Saphenous Vein Grafts) trial randomized 80 patients to either paclitaxel-eluting stent (PES) or BMS and showed significant reduction in primary end point, binary angiographic restenosis at 12 months (9% vs. 51%). [151] At 1.5 years clinical follow-up the PES patients had a significant reduction in target lesion revascularization (5% vs. 28%), target vessel failure (22% vs. 46%) and a trend towards less MI (15% vs. 31%) but increased mortality (12% vs. 5%). In contrast to the long-term results of the RRISC study, at a median follow-up of 35 months PES treated-patients had a significantly lower incidence of MI (17% vs. 46%), target lesion revascularization (10% vs. 41%), and target vessel failure (34% vs. 72%) as well as a trend toward less definite or probable stent thrombosis (2% vs. 15%). All-cause mortality (24% vs. 13%) and cardiac mortality (7% vs. 13%) did not differ between groups. [152] More evidence was provided in the ISAR-CABG (Prospective, Randomized Trial of Drug-Eluting Stents Versus Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts). In this study, 610 patients with diseased SVGs were randomized to DES and BMS and the combined incidence of death, MI, and target lesion revascularisation at 1 year was significantly lower in the DES group than in the BMS group (15.4% vs. 22.1%) which was mainly driven by a nearly 50% relative reduction in the risk of target lesion revascularization (7.2% vs. 13.1%), with non-significant differences in mortality. [153] Consistent results of improved efficacy with DES and no significant safety hazard were reported in different meta-analyses which also included non randomized trails. [154-157] The RRISC, SOS and ISAR CABG all compared first-generation DES to BMS. The SOS-Xience V (Stenting of Saphenous Grafts-Xience V) prospectively examined the frequency of angiographic in-stent restenosis in SVG lesions 12 months after implantation of everolimus-eluting stent (EES), a second generation DES. Use of EES in SVGs is associated with high rates of stent strut coverage and high malapposition rates at 12 months post implantation as assessed by optical coherence tomography, however, clinical results are to be waited. [158] Finally, in a multicenter analysis no difference was observed in real-world patients comparing first-generation DES to BMS. [159] In a meta-analysis including 29 studies (3 randomized controlled trials (RCT)) involving over 7500 patients, the authors stated that DES may decrease TVR rate in treatment of SVG stenoses but no differences in reinfarction rate, stent thrombosis or mortality was found between the DES and BMS groups in the RCT’s. [160] In contrast, the observational data showed lower risk for MI, stent thrombosis and death in the DES group. This may be a result of patient selection bias in the observational studies or represent a true finding that was not detected in the RCT analysis due to limited statistical power.
Stents are effective as treatment for focal lesions, however, the optimal treatment strategy for a diffusely degenerated SVG is uncertain. Endoluminal reconstruction with stent omplantation has been suggested as a treatment for diffuse lesions. This was evaluated in a study including 126 patients with diffusely degenerated stenosed or occluded SVG treated with stents. [161] At 3 year follow-up, survival free of death, infarction, or revascularization was only 43%.
Regarding stenting technique in SVG lesions, it has been suggested that direct stenting, compared to predilatation with balloon angioplasty, may be beneficial as trapping of debris could decrease distal embolization that may occur from repeated balloon inflations. Registry data showed that in unselected patients who underwent SVG intervention direct stenting was associated with a lower CK-MB release and fewer non-Q-wave MI. [162] These results needs to be confirmed in a prospective randomized trial.
After PCI of SVG, progression of disease outside the stented segment can lead to high rates of restenosis. Therefore, treatment of native coronary artery lesions is preferred to treatment of degenerated SVG if feasible. In addition, in patients with prior CABG, early diagnostic angiography can be important as there is a high success rate of percutaneous coronary intervention (PCI) at the time of subtotal occlusion; and the substantial consequences of the loss of a bypass graft through total occlusion (e.g, low success and high complication rates of PCI for totally occluded SVG, and difficult to control angina).
A numerous of predictors for worse outcome after percutaneous SVG intervention have been identified. Multivariate analysis revealed that major CK-MB release after SVG intervention and renal insufficiency are powerful independent predictor of all-cause mortality. [163-165] Lesion length, greater angiographic degeneration of SVG, and larger estimated plaque volume which may result in a greater likelihood of distal embolization and myocardial necrosis after intervention, have been identified as predictors of 30-day major adverse cardiac events after SVG intervention. [166,167] Sexe also appeared to be a predictor as women have a significantly higher 30-day cumulative mortality rate compared with men (4.4% vs. 1.9%), a higher incidence of vascular complications (12% vs. 7.3%), and postprocedural acute renal failure (8.1% vs. 4%). [168] Whether specific stent platforms, polymers or drugs are more appropriate in SVG and arterial graft lesions has not been addressed at this time.
Arterial graft failure - Due to the superior long-term patency of arterial grafts, in specific the IMA, they are the vascular conduit of choice for patients undergoing CABG and the increasing frequency of their use has resulted in a small but increasing need for revascularization. In arterial graft failure, ostial stenoses are the least common and the pathogenesis of ostial stenoses may be affected by its proximity to the aorta and potential extension of atherosclerosis from that vessel.
Anastomosis of IMA to the native coronary is the most frequent site of a target lesion. The particular anatomical feature of the IMA-to-LAD anastomosis is subjected to continuous mechanical stress, owing to the asynchronous motion of heart, lungs and bypass. Moreover, it has been suggested that this predilection reflects scar tissue induced by injury during surgical manipulation. [169]
Published reports have demonstrated that BA of the IMA can be performed safely with high procedural success and a low incidence of clinical restenosis. [170-175] The use of BMS compared to BA alone for percutaneous revascularization of the IMA graft was investigated in several studies. In a large cohort of 174 patients who underwent BA or BMS placement, anastomotic lesions were more evident, 63% of al cases. [169] These lesions were more commonly treated with BA (91%), whereas lesions located at the ostium (8%) were more frequently treated with stents (69%). Patients who underwent stenting had a target lesion revascularization rate of 15.4% and those who underwent BA had a rate of 5.4%. In a retrospective analysis patients undergoing BMS implantation for the treatment of IMA graft stenosis were compared to patients treated with BA. [176] The minority of patients were treated with BMS (26.4%) and received at least either ticlopidine or clopidogrel for 4 weeks post PCI. Angiographic success after stenting was high, 92%. At 1 year follow-up, target lesion revascularization rates were significantly higher in the stented lesions than lesions treated with BA alone (19.2% vs. 4.9%) and the higher rate in stented lesions was most apparent at the anastomotic site (25.0% vs. 4.2%). Moreover, a significant difference was observed between 1-year all-cause mortality between stented lesions and lesions treated with BA alone (13.6% vs. 4.4%), no difference was observed for MI. In a multivariate analysis including all available baseline factors contributing to target lesion revascularization, indicated that stent use was an independent predictor. In this observational study selection bias may have resulted in more lesions at high risk of restenosis being chosen for stenting, as stenting was at the discretion of the operator.
Comparison of BMS and DES for percutaneous revascularization of IMA Grafts, have reported conflicting results. In a retrospective study, outomes after BMS and DES treatment in IMA grafts were evaluated. [177] Baseline characteristics were comparable between the 2 groups, except for a trend toward longer stent lengths in the DES group (DES 20.2±7.7 mm vs. BMS 14.8±3.5 mm). No significant differences were present in in-hospital and 1- or 6-month outcomes between the 2 groups, including target lesion revascularization with DES (DES 3.33% vs. BMS 10%). Contrastingly, 2 small studies did not show improved clinical impact of DES compared to BMS. At 1-year clinical follow-up, no differences were detected in target lesion revascularization rates after treatment with BMS and PES (26.6% vs. 25%). [178] In the PES group, 2 late stent thromboses were observed. In addition, in a small study the long-term outcomes of 41 patients undergoing PCI of the IMA anastomosis BMS or SES were compared. [179] At a median follow-up of 29.2 months (interquartile range, 11.1-77.7 months) target lesion revascularization was 47.8% with SES and 7.1% with BMS. Patients who underwent repeat revascularization were more likely to have longer stents than those who did not (18.2 mm vs 14.2 mm).
The favourable results of BA compared to stenting in IMA graft intervention is in contrast with native coronary artery intervention. This might be explained by the fact that: 1) the proliferative response to BA in IMA may be less aggressive than that in native coronary arteries; 2) in native coronary arteries as compared to BA, stenting leads to more pronounced arterial injury, greater inflammatory response, and enhanced neointimal formation; 3) in small native coronary arteries, the high stent-to-wall ratio might predispose restenosis more frequently; and 4) stents are known to be thrombogenic and lead to neointimal formation and restenosis. [180-183]
Percutaneous treatment of ostial stenosis, presents technical challenges for the interventionalist whereas lesions in the shaft are most similar to routine intervention in a native coronary arteries. Stenting of the anastomotic site takes carefully positioning of the stent to achieve apposition to the arterial wall given the acute angle at which IMA meets the native coronary artery. In one observational study a difference in 1-year target lesion revascularization rates was present at the ostial, shaft, and anastomotic sites (30.8%, 5.0%, and 7.2%, respectively). [176] The anastomosis experiences a bending of the stent with strut shrinkage and might cause stent fracture or in DES might limit elution of drug to vessel wall.
Failure of the RA graft is most frequently a complete occlusion and less often a string-like appearance. However, on rare occasions, focal stenoses of the RA graft can occur.
RA graft stenosis treated by percutaneous intervention was evaluated in a small study including 18 patients. [184] The location of the RA stenosis was proximal (n = 2), shaft (n = 11) or distal anastomosis (n = 5). BA alone was performed on nine RA grafts at 1.7 years after surgery and stenting (3 BMS, 6 DES) of nine RA grafts was achieved at 9.2 years after surgery. At 5.8 years, clinical follow-up showed heart failure (n = 2) and recurrent angina (n = 3), all after balloon dilatation. At 4.5 years, 1 RA graft was occluded due to competitive flow from the native coronary vessel and 2 RA restenoses following BA were treated by stenting. Intra-stent RA stenosis was noted in 1 patient. PCI with BA should be restricted to the early postoperative period during which spasm is difficult to exclude. Stenting showed excellent and durable results and is preferred in most cases. There are no large studies on other arterial grafts to draw definite conclusions for the treatment with PCI by BA, BMS or DES.
Antithrombotic therapy during graft intervention - The preferred parenteral antithrombotic therapy during graft intervention remains to be explored. The role of glycoprotein IIb/IIIa antagonists in graft intervention is limited as they failed to demonstrate a reduction in periprocedural MI. [185-187] Similarly, no reduction in MACE at 30 days was observed in a post hoc analysis when glycoprotein IIb/IIIa antagonists were used in conjunction with filter-based embolic protection, although there was a trend toward improved procedural success. [188] In contrast, bivalirudin as compared with unfractionated heparin may have beneficial effects on biochemical and clinical outcomes as it was associated with a significant reduction in CK-MB elevation and a trend toward lower in-hospital non–Q-wave MI, repeat revascularization, and vascular complications. [189] Moreover, bivalirudin may offer a safety advantage over heparin plus a glycoprotein IIb/IIIa anatagonist as minor bleeding complications were lower with bivalirudin alone (26% vs. 38%) with equal or greater suppression of adverse ischemic events. [190] Pharmacological treatment of slow or no-reflow is targeted at microvascular flow with intragraft administration of vasodilators and delivery of pharmaceutical agents to the distal microvasculature and can be maximized with a microcatheter like an aspiration thrombectomy catheter. Adenosine is an endogenous purine nucleoside, a vasodilator of arteries and arterioles, and inhibits platelet activation and aggregation. A high dose of intragraft adenosine (≥5 boluses of 24 µg each) can result in reversal of slow or no-reflow and improve final Thrombolysis In Myocardial Infarction (TIMI) flow grade. However, the use of adenosine is limited because severe bradycardia may occur due to its effect on sinoatrial and atrioventricular nodal conduction and the half-life of adenosine is very short. Intracoronary administration of nitroprusside, a direct donor of NO, results in a rapid improvement in both angiographic flow and blood flow velocity. Caution is warranted in patients who are volume depleted or hypotensive at baseline because profound hypotension may occur. Prophylactic intragraft administration of verapamil (100 to 500 µg) can reduce the occurrence of no-reflow and improve TIMI myocardial perfusion grade. Prophylactic intragraft administration of nicardipine, a potent arteriolar vasodilator, may reduce CK-MB elevation. Independent predictors for slow flow or no-reflow are probable patients treated for ACS, stent thrombosis, diseased SVG, and lesion ulceration.
Embolic protection Devices - Graft intervention, in particular SVG, can be complicated by distal embolization of atheroembolic debris leading to decreased epicardial and microvascular perfusion due to capillary plugging and vasospasm from the release of neurohumoral factors. Distal embolization may result in the slow or no-reflow and is associated with periprocedural myocardial necrosis and increased in-hospital mortality. However, distal embolization remains difficult to predict. Several embolic protection devices are available to prevent distal embolization and in SVG intervention it is recommended a class I according to the ACC/AHA guideline. [191] Distal balloon systems provide occlusion beyond the lesion securing the blood and may prevent plaque embolization into the myocardial bed. Hereafter, the blood with contained debris can be aspirated before occlusive balloon deflation. Advantages are the low crossing profile and entrapment of debris of all sizes as well as neurohumoral mediators such as serotonin and thromboxane that may have an adverse effect on the distal microvasculature. However, disadvantages are: 1) the need to cross the lesion before adequate protection, possibly liberating friable material before balloon occlusion; 2) temporary cessation of blood flow leading to ischemia and possible hemodynamic instability, as well as limiting visualization making accurate stent placement difficult; 3) inability to obtain full evacuation, especially near the occlusion balloon; 4) possible traumatic injury to the SVG during balloon occlusion, and 5) the need for a relatively disease-free landing zone of approximately 3 cm distal to the lesion for placement of the occlusion balloon. [192] The PercuSurge GuardWire (Medtronic, Minneapolis, Minnesota) and the TriActiv embolic protection system (Kensey Nash Corporation, Exton, Pennsylvania) both demonstrated a significant decrease the incidence of no-reflow and improved 30-day clinical outcome but the latter was associated with more vascular complications and the need for blood transfusion. [193,194]
Distal filter systems, composed of a tightly wrapped filter attached to a guidewire and sheathed within a delivery catheter for placement distal to the target lesion, can trap debris that embolize while the intervention is performed over the guidewire. After the intervention, a retrieval catheter is advanced over the guidewire to collapse the filter and remove it along with retained contents. It is ease-of-use and antegrade blood flow during intervention is maintained to avoid ischemia allowing the ability to inject contrast media to facilitate accurate balloon inflation or stent placement. Distal filter systems may be preferred in high-risk patients who are at increased risk for hemodynamic instability such as patients with severe left ventricular dysfunction or last remaining conduit. These systems do need a high crossing profile (large diameter sheath approximately 3- to 4-F) and the maneuverability is poor. Moreover, the inability to completely entrap microparticles, possible occlusion of the filter due to large amounts of debris, and inability to use in very distal lesions because of the need for a landing zone to deploy the filter are some other disadvanteges. The FilterWire EX (Boston Scientific) and the FilterWire EX (Boston Scientific) both showed noninferiority to distal balloon occlusion devices. [195]
The Proxis embolic protection system (St. Jude Medical, Maple Groves, Minnesota), a proximal balloon occlusion device, employs a distal balloon to seals the SVG while a proximal balloon seals the inside of the guiding catheter. This secures the blood with debris from embolizing downstream into the microvasculature. After the intervention, the blood with the debris can be aspirated with a suction catheter before deflating the balloon. The advantages are that protection from distal embolization of atheromatous debris can be established before crossing the lesion, side branches can be protected, and distal lesions that are not amenable to distal embolic protection because of lack of a landing zone can be treated. The device can not be used in ostial or very proximal lesions as approximately 15 mm of landing zone is required, and the device causes cessation of antegrade perfusion resulting in myocardial ischemia. The multicenter prospective randomized PROXIMAL trial determined outcomes of the Proxis embolic protection device compared to distal protection devices during stenting of degenerated SVG. [196] In a subset of 410 patients with lesions amenable to treatment with either proximal or distal protection devices the primary composite end point, death, MI, or target vessel revascularization at 30 days, occurred in 12.2% of distal protection patients and 7.4% of proximal protection patients.
The decision regarding whether or not to intervene in a diseased graft should be guided by the patient’s symptoms, angiographic evidence of a significant stenosis, and noninvasive evidence of myocardial ischemia in the region subtended by the bypass graft. Fractional flow reserve (FFR) measurement to assess the significance of stenosis in a bypass graft can be performed in a similar fashion as in a native coronary vessel and guide decision making.
Moreover, risk-scoring models are considered to be valuable in predicting outcomes and guiding to appropriate treatment strategies for patients undergoing PCI. Although, the SYNTAX score, developed to characterize angiographic complexity, has been proposed to predict outcomes and select an optimal treatment strategy for patients with coronary artery disease, the score is complex and does not take into account patients with coronary bypass graft lesions. [197-199] The Duke myocardial jeopardy score was developed in the 1980s as a simple method to estimate the amount of myocardium at risk for ischemia on the basis of the location of a coronary lesion in non-surgically managed patients with coronary artery disease.[200] Recently, an adjustment was suggested to this score to include left main disease as well as the protective properties of patent bypass grafts, the modified Duke jeopardy score (Figure 1). [201] The same assumptions are used as in the original score, assigning greater prognostic significance to more proximal lesions than more distal lesions in the same vessel. Noteworthy, the modified Duke jeopardy score has not been validated yet.
Modified Duke Jeopardy Score
Acute coronary syndrome - After CABG, progression of atherosclerosis occurs both in grafts and native coronary arteries, resulting in significant morbidity and mortality, especially in patients who present with acute ACS. Estimates from the Coronary Artery Surgery Study and Veteran’s Affairs Cooperative Study of Coronary Bypass indicate a rate of MI of approximately 2% to 3% per year over the first 5 years after CABG, with recurrent infarction in as many as 36% of patients at 10 years and even higher rates of hospitalization for recurrent ischemia. [202-204] Although primary PCI is the preferred strategy for STEMI patients, current guidelines do not provide specific recommendations on the optimal reperfusion strategy in patients with prior CABG. [205] Compared to patient without prior CABG, patients with prior CABG presenting with ACS are older, have more cardiovascular risk factors, more frequent comorbidities, higher TIMI risk score, lower left ventricular ejection fraction, had higher prevalence of previous treatment with evidence-based medications, were less likely to have ST-segment deviation or positive cardiac biomarker on presentation. [206-209] During hospitalization prior CABG patients experienced larger infarct size, were less likely to receive reperfusion therapy, early invasive therapy and were more likely to be managed medically when compared to non-CABG patients. [207,209] However, the efficacy of reperfusion therapy in patients with previous CABG is less well characterized. Given the large amount of atherosclerotic material and thrombus burden with limited runoff found in occluded SVG, it is suggested that reperfusion success rate is reduced. In the GUSTO-1 (Global Utilization of Streptokinase and TPA for Occluded Arteries I) trial a significantly increase in 30-day mortality was observed following reperfusion with tissue-type plasminogen activator in prior CABG patients compared to those without prior CABG (10.7% vs. 6.7%). [210] In addition, the prior CABG group also suffered more pulmonary edema, hypotension, or cardiogenic shock and a lower TIMI flow grade 3 rate was achieved (31% vs. 49.2%). In the PERSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) trial the efficacy of eptifibatide, a Glycoprotein IIb/IIIa antagonist, in patients with ACS was compared in patients with or without prior CABG. [88] After adjusting for differences in baseline characteristics and treatment, patients with prior CABG had a significantly higher mortality rates at 6 months. At 30 days, there was a similar effect on the primary end point of death or MI in the eptifibatide group versus the placebo group in prior CABG patients and in patients without a history of CABG. Finally, in the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial patients with prior CABG presenting with ACS were randomized to bivalirudin or heparin plus a glycoprotein IIb/IIIa inhibitor. [209] Bivalirudin monotherapy did not improve short-term or long-term prognoses in ACS patients with prior CABG. Currently, the optimal antithrombotic therapy for patients with prior CABG presenting with ACS is not known, and existing data are conflicting.
As the non-invasive treatment did not significantly improve outcomes in patients with prior CABG presenting with ACS a percutaneous strategy was investigated. Invasive versus non-invasive treatment in ACS and prior CABG was evaluated in the GRACE (Global Registry of Acute Coronary Events), and 6-month mortality was lower in patients revascularized versus those treated medically by univariate but not by multivariable analysis. [211] Similarly, in a large Swedish registry of 10,837 patients with previous CABG, 1-year adjusted mortality was reduced with 50% with revascularization compared with medical management. [212]
Long-term clinical follow-up of ACS patients with prior CABG treated with PCI has been assessed in several studies. In a small study, 34 consecutive patients with ACS who underwent PCI with DES for occluded SVG, showed a procedural success rate of 81%. [213] At 3-year follow-up mortality was 42%, recurrent ACS was 41% and repeat intervention was 38%. In a recently published retrospective analysis, the outcomes after PCI with BMS or DES for ACS due to graft failure were evaluated. [214] Although the majority of the 92 patients included were treated with BMS (84%), the groups were comparable for baseline clinical and angiographic characteristics. Graft failure occurred mainly in the SVG (90%), but also arterial grafts (LIMA and RIMA) were treated (8.7%). The initial restoration of normal blood flow was approximately 80%. The primary endpoint of death, MI, target vessel revascularization at 5-year follow-up was 65.9% in the BMS group and 43.4% in the DES group, this difference did not reach statistical significance. Individual endpoints at 5 years were also comparable between BMS and DES groups (death 46% vs. 43%, MI 36% vs. 33%, target lesion revascularization 26% vs. 15%, respectively). Predictors for the composite endpoint were cardiac shock (HR= 6.13; 95%-CI:3.12-12.01), creatinin (HR=1.006; 95%-CI:1.001-1.011), and multi-vessel disease (HR= 4.64; 95%-CI:1.40-15.41). Cardiac shock and creatinin also predicted for death.
The beneficial effect of redo CABG over PCI was examined in the randomized AWESOME (Angina With Extremely Serious Operative Mortality Evaluation) trial in which 3-year survival and freedom from recurrent ACS was similar among patients with prior CABG and refractory myocardial ischemia, although patients favoured PCI. [215]
Patients with an acute MI / STEMI from a SVG culprit undergoing PCI are a high-risk subset of an already high-risk population. In the PAMI-2 (Second Primary Angioplasty in Myocardial Infarction) trial demonstrated lower angiographic success rates and higher mortality rates after BA in 58 patients with prior CABG compared with the 1068 patients without prior CABG. Primary PCI in patients with acute MI and prior CABG showed that patients treated with BA or BMS in SVG grafts compared to patients in whom a native vessel was treated had more no-reflow at initial treatment (8.9% vs. 1.6%) and significantly more MI at 1 year follow-up (26% vs. 11%). [130] In another study, outcomes of 192 patients with acute MI from a SVG culprit undergoing PCI were compared to patients with a native culprit. [216] After multivariable adjustment, SVG culprit remained significantly associated with lower levels of peak troponin. The likelihood of MACE was higher in SVG vs. native culprits in patients with small to modest troponin elevations. Patients with a SVG culprit also suffered higher rates of mortality at 30 days (14.3% vs. 8.4%) and MACE at 1 year (36.8% vs. 24.5%). Finally, in the APEX-AMI trial, STEMI patients with prior CABG exhibited a smaller baseline territory at risk as measured by 12-lead ECG and had less myocardial necrosis. Moreover, in these patients receiving primary PCI, TIMI flow grade 3 was less frequently achieved and ST-segment resolution was less common but they have more frequent clinical comorbidities and increased 90-day clinical events including mortality. Risk factors for mortality were prior heart failure and age.
In conclusion, in patients with prior CABG presenting with ACS, PCI improves clinical outcomes compared to medical therapy alone. Redo CABG does not seem to further improve clinical outcomes.
Redo CABG is considered when revascularization of the LAD or a large area of the myocardium is required. Redo CABG is also preferred in patients with prior CABG with no patent grafts present but left main disease or 3-vessel disease, and in those with disabling angina, despite optimal non-surgical therapy, including lesions unsuitable for PCI. [217]
Surgeons are posed with a number of challenges in patients requiring redo CABG, including a higher likelihood of technical complications, incomplete revascularization, inadequate myocardial preservation, lack of suitable conduits, neurologic complications including major disabling stroke, renal failure, peri-operative bleeding and ischemia. [218,219] To help decrease the risks associated with redo CABG, a number of technical advances have been introduced in the surgical arena. The first challenge, safe sternal re-entry without damaging coronary bypass grafts and other retrosternal structures, has been described to be safely performed when using an oscillating or micro-oscillating saw. [220,221] Periodic deflating of the lungs will help prevent injury to the pulmonary parenchyme during re-entry. When a mammary artery was used in the first surgery, there are generally four types of mammary artery to sternal relationships that can be encountered. [219] The first: LIMA and RIMA are both used with the LIMA supplying the LAD and the RIMA reaching to the RCA or its branches. In this case, the risk of injury is relatively low, because the IMA grafts are parallel to the body of the sternum at a deeper plane and go through the pericardium (which is therefore open) directly away from the midline toward the target vessels. In a second situation, a pedicle LIMA graft crosses in front of the pleura, curves around and goes back laterally to reach the LAD, which is typically seen as a C-shaped curve on the angiogram. This type of LIMA grafting is particularly prone to injury during sternotomy because of its close proximity to the sternal body. In the third scenario, the RIMA graft is used and comes in front of the aorta across the midline and reaches the LAD. Although the graft crosses the midline the risk of injury is relatively low due to the close proximity to the aorta which lies deeper in the thorax and can be easily identified. Finally, the RIMA may go behind the aorta through the transverse sinus to reach the marginal branches of the Cx artery, which is very far away from the sternal re-entry area and poses therefore minimal risk for potential injury. The proximity of vein grafts to the sternum varies significantly due to the large number of options for proximal as well as distal anastomosis sites. Careful review of the coronary angiogram or even cardiac/thoracic imaging to assess the relationship to the sternum and other anatomic structures is therefore warranted. Other structures at risk for injury during sternal re-entry include perforation of the right ventricle, and innominate vein. This is particularly true in patients where the pericardium was not closed. After sternal access, subsequent exposure of the heart can be completed by fibrosis which can be significant especially after pericarditis or radiation exposure. In patients requiring posterior vessel bypass, the entire heart should be cleared of fibrosis to allow surgical manipulation.
After sternal entry and inspection of the coronary vessels and branches, the second challenge is to assure adequate revascularization. Diffuse coronary artery disease poses a major problem in finding a suitable and satisfactory area for anastomosis. Thick plaque build-up and calcified coronary artery branches as well as calcification of the aortic arch make distal and proximal anastomosis of coronary bypass grafts hard and increase the chances of graft failure. [219] Additionally, the lack of satisfactory bypass conduits is common, because many patients undergoing redo CABG have very thin and dilated varicose veins, and small and calcified radial arteries. Risk factors for poor saphenous vein quality are age, obesity and diabetes, which are all more prominent in patients requiring redo CABG. In those patients the IMA may be small or even atherosclerotic.
Inadequate myocardial protection is an important cause of failure to wean patients off cardiopulmonary bypass. In the presence of degenerative old vein grafts, delivery of cardioplegia solution is considered safer through retrograde coronary sinus perfusion than anterograde delivery of cardioplegic solution because of the risk of atheromatous embolization from atherosclerotic vein grafts which can lead to acute occlusion of coronary artery branches. [222] Additional measures include a no touch approach regarding diseased vein grafts to minimalize the chance of distal embolization due to manipulation. [223] To assure a constant temperature in an attempt to minimize haematological abnormalities and tissue edema, some surgeons also occlude the IMA with a bulldog clamp to prevent the delivery of warm blood into the myocardium. In such a way, the entire myocardium is provided with continuous, cold cardioplegic solution through coronary sinus perfusion. [224,225] After placement of newly constructed coronary artery bypass grafts, anterograde cardioplegic solution can also be given.
Neurological complications and bleedings are common following redo CABG. Several techniques are used to decrease the risk of neurological complications. Most common are ischemic stroke or TIA due to cerebral embolization from a calcified ascending aorta, atheromatous plaques on the ascending aorta, and embolization from a jet phenomenon from aortic cannulation. Other causes for cerebal dysfunction are systemic inflammatory processes in response to cardiopulmonary bypass and gaseous microemboli. [226] Soft flow aortic cannulae, heparin-coated circuits, and administration of adenosine have proposed as techniques to lower neurological complications, but adequate studies and therefore evidence are lacking. [227-229] Bleeding is associated with an increased morbidity and mortality. Bleedings can be largely avoided by meticulous surgical dissection and careful catherization. Some studies using the application of fibrin glue suggest that this may help minimize peri-operative bleeding. [230] Intraoperative blood loss is a major cause of post-operative bleeding from depleted coagulation factors and hemodilution. Consideration should be given to preoperative antiplatelet therapy including aspirin and clopidogrel. A low platelet count and other medical conditions that adversely affect the coagulation process should be carefully investigated.
Redo CABG for coronary bypass graft failure is not favoured by cardiologists and surgeons alike, due to the higher morbidity and mortality compared with primary CABG. Reported intraoperative mortality rates are 5.8-9.6%. [231] Other major complications include stroke (1.4-3.2%), non-fatal MI (3.0-9.6%), renal failure (2.4-11%) and post-operative bleeding (2.7-4.4%). [217,223] Following redo CABG, survival is 75–90% and 55–75% at 5- and 10-year follow-up, respectively. [231]
Redo CABG versus PCI - Available data comparing the outcomes of PCI to redo CABG in patients with prior CABG is limited. Initial studies evaluating BA versus CABG noted comparable long-term results except for a much higher rate of repeat revascularization in the BA group (BA 64% vs. redo CABG 8%). [232] Multivariate analysis identified age > 70 years, left ventricular ejection fraction < 40%, unstable angina, number of diseased vessels and diabetes mellitus as independent correlates of mortality for the entire group. Direct comparison between redo CABG and PCI was performed in the AWESOME trial. A total of 142 patients with refractory post-CABG ischemia and at least one of five high-risk features (i.e. prior open-heart surgery, age >70 years, left ventricular ejection fraction <35%, MI within seven days or intraaortic balloon pump required) amandable for either PCI or redo CABG were randomized. [17] Arterial grafts were used in 75% of redo CABG procedures and stents in 54% of PCI (approximately one-half with BMS). In-hospital mortality was higher after redo CABG (8% vs. 0%). At 3 years, there was no significant difference in overall patient survival (redo CABG 71% vs. PCI 77%), but there was a nonsignificant increase in survival free of unstable angina in the CABG group (65% vs. 48%). In the much larger retrospective observational study from the Cleveland Clinic of 2191 patients with prior CABG who underwent multivessel revascularization between 1995 and 2000 were evaluated. [233] A total of 1487 had redo CABG and 704 underwent PCI (77% with at least one stent). No difference was observed in 30-day mortality with redo CABG compared to PCI (2.8% vs. 1.7%) but as expected periprocedural Q wave MI occurred more often after redo CABG (1.4% vs. 0.3%). At 5-years follow-up, cumulative survival was similar with redo CABG and PCI (79.5% vs. 75.3%). After adjustment, PCI was associated with a nonsignificant increase in mortality risk (hazard ratio 1.47, 95% CI 0.94-2.28). The major predictors of mortality were higher age and lower LVEF, not the method of revascularization. Importantly, the choice of treatment strategy was largely determined by coronary anatomy wherein the most important factors to perform redo CABG were: 1) more diseased or occluded grafts, 2) absence of a prior MI, 3) lower left ventricular ejection fraction, 4) longer interval from first CABG (15 vs. 6 years), 5) more total occlusions in native coronary arteries, and 6) the absence of a patent mammary artery graft.
In diabetic patients with post-CABG angina, the outcomes after repeat revascularization were evaluated in an observational study in which 1123 such patients underwent PCI (75% BA, 25% stent palcement) and 598 underwent redo CABG. [234] Redo CABG was associated with increased in-hospital mortality (11.2% vs. 1.6%) and stroke (4.7% vs. 0.1%). At 10 years, there was no significant difference in mortality between groups (redo CABG 74% vs. PCI 68%). Noteworthy, the available comparative studies were, however, conducted before the use of aggressive dual antiplatelet therapy with aspirin and clopidogrel after PCI with stenting and aggressive lipid-lowering with statins for secondary prevention.
In a recently published retrospective study, in which patients were prescribed aggressive dual antiplatelet therapy, 287 consecutive patients with graft failure were assigned by the heart-team to PCI or redo CABG. [235] A total of 243 patients underwent PCI (82% treated with BMS, 18% treated with DES) and 44 redo CABG. Patient selection was present as patients undergoing PCI more frequently presented with STEMI, multivessel disease, SVG failure, a history of MI, and shorter time-to-graft failure. At 5 year, the rate of composite all-cause death, MI or target vessel revascularization was comparable, 57.6% after PCI and 51% after redo CABG. Target lesion revascularization was 21.3% after PCI, and 3.2% following redo CABG. In the PCI group, BMS was associated with significantly higher rates of target lesion revascularization (24.8% vs. 7.6%), but the rate of death or MI compared with DES was similar. Independent predictors for the composite outcome were creatinine and peak creatine kinase MB. These results have to be confirmed in larger studies before definite conclusion can be drawn.
Patients with prior CABG remain at risk for future cardiac events, including graft failure. Stable patients with recurrence of angina following CABG can be treated medically for their symptoms and risk factor reduction. In all patients with coronary heart disease aggressive risk factor reduction is recommended which includes aspirin, treatment for hypertension and serum lipids, avoidance of smoking, and controlling serum glucose in diabetic patients. Evaluation for ischemia is as in other patients with stable angina without prior CABG. However, early diagnostic angiography is suggested as the different anatomic possibilities, i.e. graft stenosis or progression of native vessel disease in nonbypassed vessels can lead to recurrent ischemia. Revascularization of graft failure either by PCI or redo CABG is associated with worse acute and long-term outcomes compared to patients without prior CABG. The choice of treatment modality is influenced by clinical and angiographic characteristics. When multiple grafts are occluded or the graft or native coronary artery appears unsuitable for PCI, surgery should be favoured. The target for PCI is the body of the coronary artery of the arterial graft while freshly occluded SVG or the anastomosis itself should be targeted due to the risk of embolization or perforation. Whether specific stent platforms, polymers or drugs are more appropriate in SVG and arterial graft lesions has not been addressed at this time. Moreover, the role of various surgical techniques for graft revascularization, such as off-pump and minimal invasive CABG also remain unclear. Finally, factors including disease status of the native vessel, and patient characteristics such as left ventricular function, renal failure, diabetes and advanced age, as shown in our multivariate analysis are of influence on outcomes. Future prospective studies in the medical and invasive treatment of graft failure are therefore warranted. Those studies together with our growing understanding of the pathobiology of arterial and vein grafts will ultimately result in practical patient-tailored therapeutic strategies to enhance graft function and control intimal hyperplasia and accelerated atherosclerosis.
Four hundred years back, Paracelsus stated that, “All substances are poisons; there is none which is not a poison.” If the right dose is taken, it could become a remedy, otherwise poisonous [1, 2]. The therapeutic index or ratio, i.e., LD50/ED50, tells whether the chemical is safe or not.
Poisons are generally found in cases of homicides, suicides, or accidents. They have a significant role to play as the silent weapon to destroy life mysteriously and secretively.
Every poison has almost similar action on the victim’s body. In many cases, they either stop the transfer of O2 to the tissues or create an obstacle in the respiratory system by inhibition of enzymes which are associated with the process. In this, the myoneural junction and the ganglions and synapses are the sites of action. In some cases of insecticidal poisoning, hyperexcitement of voluntary and involuntary muscles can cause death. There are four categories of action of poisons—(i) local action, (ii) remote action, (iii) local and remote actions, and (iv) general action.
Local action: Local action means direct action on the affected site of the body. Examples include irritation and inflammation in strong mineral acids and alkalis, congestion and inflammation by irritants, the effect on motor and sensory nerves, etc.
Remote action: Remote action affects the person due to absorption of that poison into the system of that person. For example, alcohol is absorbed in the system and then it affects the person.
Local and remote actions: Some poisons can affect both local and remote organs. Thus, they not only affect the area with contact to the poison but also cause toxic effect after absorption into the system, for example, oxalic acid.
General action: General action means the absorbed poison affects more than one system of the body, for example, mercury, arsenic, etc.
Toxicity of a poison depends upon its inherent properties such as physiochemical as well as pharmacological properties.
The action of poisons mainly depends upon the following factors discussed below:
Forms of poison: There are three forms of poison:
Physical form: Gaseous/volatile/vaporous forms of poisons act faster than liquid poisons as they are quickly absorbed. Similarly, liquid poisons act faster than solid poisons.
Gaseous or volatile > liquid > solid.
For solid poisons, powdered poisons act quickly than the lumps. For example, there are certain seeds that escape the gastrointestinal tract as they are solid, but when crushed, they can be fatal.
For solids: powdered > lumps
Chemical form: Few substances like mercury or arsenic are not poisonous as they are insoluble and cannot be absorbed when they are in combination with other substances like mercuric chloride, arsenic oxide, etc.
In other cases, the action is vice versa. For example, there are some substances that become inert in combination with silver nitrate and hydrochloric acid and are deadly and poisonous when present in pure forms.
Mechanical combination: The effect of poisons is significantly altered when they are combined with inert substances.
Quantity: Large doses of toxin cause much lethal effect. But this statement is not always true. For example, sometimes when a toxin is taken in very large amount, the body produces a mechanism against it such as vomiting, and thus the intensity of the toxin is reduced.
Concentration: The absorption speed of poison is dependent on concentration; thus poison of higher concentration is fatal. However, there are still some exceptions. For example, a dilute oxalic acid is less corrosive, but the absorption rate is high and so it is more dangerous.
Methods of administration: It has a unique role in the process of absorption. It is fastest through inhalation and then through injection as compared to the oral mode.
Condition of the body: Different persons react differently when exposed to a poison. It is because the condition of our body is also responsible for the increase or decrease of the effect of a poison on the body:
Age: Children and older people are more affected than an adult by the same quantity of toxin.
Sleep: The body functions are slower during sleep; thus toxin circulation in the body is also slower.
Health: Healthy persons can tolerate a toxin better than a weak or ill person.
Dosage: The effect of the poison depends upon its dosage. It is said that the dose determines whether a substance is a poison or remedy. A substance is usually considered a poison after a certain fixed quantity. Although this quantity is not fixed for all people, it is considered according to the average effect on the population. There are two considerable effects of poison on the body of a person; these are the subtle long-term chronic toxicity and immediate fatality.
Some poisons are lethal in microquantities, while others can affect in large doses. The significance of a dose can be understood by taking an example of a metal essential in the food, for example, iron, copper, manganese, zinc, etc.; if its dose is higher than the body requires, it can be lethal.
Effective dose (ED): The effective dose is the quantity of a substance at which it shows its effect in the population. In most cases, ED50 is measured as a dose which induces a response in half of the targeted population.
Lethal dose: The lethal dose (LD) 50 is the amount of drug which is expected to cause death of 50% population.
Hypersensitivity: It is basically the type of reaction initiated by the body against any other substances. Sometimes, it could be related to allergy. There is an assumption that hypersensitivity does not depend on wrong doses. Every person who is hypersensitive to a particular substance has a dose related that defines the quantity required to cause hypersensitivity to that person. The allergic response is actually a toxic response and can be sometimes fatal.
Idiosyncrasy: It is defined as a reaction produced by the body to a chemical genetically. It is a type of person that affects only those people who are genetically sensitized to that particular chemical or substance but will show no effect on others. In such cases, the person experiences discomfort for several hours or if the dose is high can be fatal also. For example- peanut allergy in some people.
Tolerance: It is the capability of a person to not produce any effect against a chemical that usually causes reaction to normal persons. It is a state of reduced or no reaction to a chemical. There are basically two types of mechanism that induces tolerance. First is when the toxin reaches the effective site, its quantity is very less. This is called dispositional tolerance. The second is because the tissues show reduced response to the toxin.
Tolerance can also be achieved if a drug is taken in a small quantity on a regular basis. This can be explained by taking the example of alcohol. When any human consume alcohol for the first time, he/she will show an effect even when the quantity is small, but eventually the effect will decrease and the person can tolerate a large amount also.
Individual susceptibility: It is defined as the different kinds of responses produced by different individuals to a particular harmful compound. It can be due to occupational or environmental factors and exposures. It is determined by complex genetic factors. Its effect depends upon the intensity of exposure. There is a gene uniqueness that varies from person to person; thus the same amount of exposure can show no effect in one individual, cause illness to other individual, and also could be fatal to someone as well.
The route of administration is the path through which a drug, toxin, or poison is taken or administered into the body of a person which is distinguished by the location where any drug is applied. It is mostly classified on the basis of its target:
Topical—which has a local effect
Enteral—which has a wide effect, i.e., affect the whole system
Parental—which follows a systemic action
Poisons are given or taken so that death can occur at once by shock due to stoppage of body’s vital systems. Drug addicts take drugs through inhalation or injection.
Route of administration plays a very important role in determination of death by poison as time in which death occurs are fastest in inhaled poisons, relatively slow in injected and lastly when ingested orally.
Some important features that are considered during the administration of poisons and can make a poison fatal are:
Rate of dissolution of the poison that depends upon the physical form of the poison, i.e., gaseous, vapors, liquid, solid, etc.
The surface area affected at the site of administration of the poison
The circulation rate of blood in that route
The solubility of the poison, i.e., lipid soluble or water soluble
The concentration of the poison
The time required by the poison to be absorbed completely from the site of administration
Routes of administration can be classified into two categories:
Enteral routes/gastrointestinal routes.
Parenteral routes.
Enteral routes: When the drug is administered through the gastrointestinal tract, it is defined as an enteral route. It has both oral and rectal routes. It also includes sublingual and sublabial routes. It is comparatively a slower mode of action for absorption of drugs:
Oral route: Generally absorption takes place in the tongue and the gums of the oral passage. The pH of the buccal cavity and mouth ranges from 4 to 5. Sublingual and supralingual routes have a significant role in absorption. The sublingual absorption is faster as the toxin is transformed directly to the heart, but it takes more time.
Rectal route: Administration of drugs can be done through anus which directly absorbed in bloodstream through membrane of mucous. This administration can cause the burning of tissues or bleeding in rectum as the area is very sensitive.
Parental route: It includes all the other routes that does not involve the gastrointestinal tract. It has a systemic effect on the body. It has the following categories of administration:
Intradermal: Here, the administration of drugs takes place from surface of skin. This type of poisoning is mostly found in chronic poisoning cases.
Intravenous: It is one of the fastest modes of drug administration as the injection is directly taken and the drug is transferred directly into the veins and thus is directly circulated into the blood quickly. Immediate death might be caused by this type of drug.
Intraosseous: It involves an administration of a drug directly into the bone marrow. This mode is actually used for administration of drugs for medical purposes.
Intra-arterial: It involves an administration of a drug into the artery directly through injection. It is a fast mode of administration.
Intramuscular: In this mode, the drug or poison is administered into the muscle of the thigh, upper arm, or buttock. The time required in this mode is greater than other parental modes.
Subcutaneous: In this mode, the drug is injected into the layer beneath the skin, i.e., the subcutaneous layer. The drug then goes to the small blood vessels and then to the bloodstream. This mode is used for mostly those protein drugs that would be destroyed if administered through the gastrointestinal tract.
Inhalation: In this mode, the nose is the primary path. Because of the presence of mucous membrane, the nasal aperture is very absorptive. The microparticles of poisons are easily absorbed and transported quickly to the lungs. From the lungs, they are circulated into the blood.
Poisons are classified into two ways:
Based on their action on the body.
Based on their physical and chemical properties [1].
Classification based upon the effect of poison on the body:
Corrosive: The poisons burn the tissues or organs when they come in contact with them, e.g.:
Strong acids such as H2SO4, HNO3, HCL, etc.
Strong alkalis such as hydroxides of Na, K, NH4, etc.
Irritants: The poisons irritate the tissues or organs when they come in contact with them [3]:
Inorganic:
Nonmetallic phosphorous, chlorine, bromine, iodine, etc.
Metallic salts of arsenic, antimony, mercury, copper, lead, zinc, etc.
Organic:
Vegetable—castor oil, madar, croton oil, etc.
Animals—snake venom, cantharides, insect bites, etc.
Mechanical—glass powder, needles, diamond dust, hair, etc.
Neurotics: Poisons affect the nervous system and the brain [3]:
Cerebral:
Narcotic—opium and its alkaloids
Inebriant (depressant)—alcohol, ether, chloroform, and chloral hydrate
Spinal:
Excitant (stimulants)—nux vomica and strychnine
Depressant—gelsemium
Cardiorespiratory:
Cardiac—aconite, digitalis, oleander, and hydrocyanic acid (HCN)
Asphyxiants—carbon monoxide, carbon dioxide, and hydrogen sulfide
Miscellaneous: A number of chemicals having diverse actions on their body are included in this group [4]:
Animal poisons
Curare (an arrow poison)
Poisonous food articles
Industrial poisons—methyl isocyanate (MIC)
Fuels—petroleum and kerosene
Insecticides—endrin, dichlorodiphenyltrichloroethane (DDT), and
naphthalene
Radioactive substances
Classification of poisons based upon their properties:
Inorganic poisons
Metallic poisons:
Arsenic: It has been the most known and exclusively used throughout
the ages to poison men and animals [1].
It is a white tasteless powder and a pinch of the poisons can kill two adult persons.
Arsenic for homicidal purposes is mixed with various food articles, e.g., cooked food, milk, tea, liquors, or medicines.
Arsenic in a metal form is not poisonous; its oxides are highly poisonous. It is extensively used in insecticides, etc. [5].
Mercury: Chloride and nitrites of mercury are highly poisonous. They
are used in chemical industry and as fungicides.
Lead: Most of its compounds are poisonous. This is a slow poison,
e.g., Sindoor adulterated with red lead oxide.
Copper: Its salts are used in electroplating; copper sulfate is a poison.
Thallium: Thallium salt is used as rat poison [6].
Antimony: Its effect is like that of arsenic.
Nonmetallic poisons:
Cyanides: Cyanides of potassium and sodium are extremely
poisonous, even in small quantities. They react with the acid of
gastric juices in the stomach to form hydrocyanic acid, which
paralyzes the respiratory center in the brain resulting in death due to
respiratory failure [4].
Yellow phosphorus: In olden days it was used in match industry and
several times proved highly poisonous.
Iodine: Only elemental iodine in high quantity is poisonous.
Strong acids and alkalis: These are highly poisonous with corrosive
effects, e.g., sulfuric acid, nitric acid, sodium, potassium
hydroxides, etc.
Gases: Phosphine gas kills rats when used on the rat holes and is
poisonous for infants. MIC killed over 2000 persons and invalidated
several others in a gas leak tragedy in Bhopal in 1984. Some other
poisonous gases are HCN, carbon monoxide, hydrogen sulfide,
arsine, etc. [3].
Organic poisons
Volatile poisons:
Ethyl alcohol: It is poisonous if taken in excess.
Other alcohols: Methyl alcohol and isopropyl alcohol are poisonous.
Methanol, used in polish and chemical industries, is used in illicit
liquor, and its intake causes paralysis, blindness, and death [3].
Phenol: Phenol or carbolic acid could be poisonous. It is mostly used
as a disinfectant [6].
Miscellaneous substances: Various industrial chemicals like
chlorinated hydrocarbons, benzene, chloral hydrate, etc. are
poisonous. In several cases of poisoning, chloral hydrate could be
used in illicit liquors.
Nonvolatile substances:
Alkaloids: Several narcotics and vegetable poisons contain alkaloids,
e.g., strychnine, morphine, cocaine, nicotine, etc.
Barbiturates: These drugs are synthetic and induce sleep [1].
Glycosides: These drugs can cause cardiac arrest and could be fatal
such as aconite, oleander digitalis, etc.
Insecticides and pesticides
Poisoning: It is known as the injurious effect caused by the action of a poison or a detrimental chemical substance. It leads to the development of adverse reaction toward the harmful chemicals or drugs. It is basically differentiated in three categories: suicidal, homicidal, and accidental. Cattle poisoning is the poisoning related to animals. Accidental poisoning is caused by negligence and carelessness. Homicidal poisoning includes the killing of a person due to the poison. Suicidal poisoning refers to the use of toxic chemicals in order to kill oneself.
Corrosive poisoning: It is caused by poisons such as acids and alkalis. They produce a corrosive action on the human body by causing ulcers and acute inflammation.
Metallic poisoning: Metals such as arsenic, mercury, lead, etc., when ingested, cause a deleterious effect. This is known as metallic poisoning.
Plant poison: The study of plant poisons is known as phytotoxicology. Plant poisons, or phytotoxins, comprise a vast range of biologically active chemical substances, such as alkaloids, polypeptides, amines, glycosides, oxalates, resins, toxalbumins, etc.
An alcohol is a drink that contains ethanol. Ethanol is made by fermentation of grains, fruits, and some resources of sugar. Chemically, it is a group of compounds whose saturated carbon chain has a “-OH” group. Alcohol is also a depressant, and in low dose, it can reduce tension, cause euphoria, and improve sociability, but in high dose it can cause stupor, drunkenness, and even death. Regular alcohol intake can cause cancer, alcoholism, dependency, etc. 33% of the total people in the world consumes alcohol. Drinks containing alcohol are broadly classified into three classes, i.e., beer, spirit, and wine, whose alcohol content varies between 3% and 50%. When diluted, alcohol has nearly sweet taste, but when concentrated it gives a burning sensation. 90% of the absorbed alcohol is metabolized by the liver and broken down into less toxic metabolites. Alcohol acts on the central nervous system (CNS) as a depressant on the cells of the cerebral cortex. Its adverse effects like a decrease in cognitive and psychomotive skills are well documented. Alcohol percentage (ABV) differs from one brand to another, for example, beers contain 5%, wines contain typically 13.5%, fortified wines contain 15–22%, spirits contain 30–40%, fruit juice contains less than 0.1%, and cider/wine coolers contain 4–8% ABV [1].
The goal of blood alcohol test is to check the concentration of alcohol in the body. This test result is known as blood alcohol concentration (BAC) which indicates alcohol % in the blood. It is directly proportional to the alcohol in the body, and alcohol hinders with people’s decision, control on them and other characteristics [3]. This test can tell the presence of alcohol in blood for 12 hours [4]. Blood quickly absorbs alcohol and is measured within minutes of consuming alcoholic drink. The highest level of BAC result can be reached within an hour of consuming alcohol. Intake of food can vary the result. Liver breaks down almost 90% of alcohol and rest are given out from exhalation and urine [5].
In case of deaths due to alcoholic intoxication, the viscera is collected and preserved in saturated saline. Preservation of sample is very important as if wrongly preserved it can ruin the examination. Generally, urine and blood are taken as samples.
A sterile needle must be cleaned up by the swab of a nonalcoholic disinfectant like aqueous mercuric chloride and aqueous benzalkonium chloride (Zephiran) before the suspect’s skin is punctured with it. The use of an alcoholic disinfectant either may give false-positive results or may contribute to falsely high alcohol contents of blood. About 5–10 ml of the sample (blood) is taken in a test tube; an anticoagulant such as potassium oxide and EDTA and a preservative such as NaF are added and stored in the refrigerator at 40°C. The anticoagulant will prevent blood from clotting, and the preservative will inhibit the presence of microorganisms. The urine sample is also collected in the usual manner and preserved with 30 mg of phenyl mercuric nitrate for every 10 ml of urine [6].
Ethyl alcohol is isolated from biological materials by acid distillation. Viscera, vomit, stomach contents, and other materials should be analyzed separately. About 50–100 g of the viscera is taken and is finally minced by thin gruel and adding water (3–5 times) and sulfuric acid. It is passed to steam distillation which is generally heating it on the water bath. The condenser and the receiving flask should be well cooled with ice especially in the hot season, the outlet of the condenser being dipped in little water or NaOH solution. Some pieces of pumice stone are stored in the flask to avoid bumping. It is better to collect the distillate in 4–5 fractions, out of which the first one should not exceed 20 ml and the remaining fractions should be 50 ml each. The distillate contains alcohol and other volatile acids, etc. [6].
There are some tests which show the presence of ethyl alcohol in the exhibits.
Also known as triiodomethane reaction, it is used in the detection of CH3CH (OH) which is present in alcohol. There are mainly two types of different mixtures used in this reaction which are mainly chemically equivalent. A pale yellow precipitate occurs if the result is positive [6].
In the above structure, “R” can be hydrogen or alkyl group or any other hydrocarbon group. In case when R denotes hydrogen, then the compound we have the possibility to find is primary alcohol ethanol. Ethanol is the only alcohol that gives an iodoform reaction. In case R is any hydrocarbon group, then it gives secondary alcohol groups. Tertiary alcohol is not able to contain R group because of the absence of hydrogen atom [7].
In 1 ml of distillate, a few drops of 10% NaOH are added dropwise till the solution becomes brown and warmed for a few minutes. A few drops of iodoform solution are added to change the color to yellow. The mixture has to be again heated on low flame/water bath; a yellow-colored precipitate is formed on standing. The precipitate has to be observed under a microscope. Characteristic hexagonal crystals of iodoform are seen which usually shows the presence of ethanol, acetaldehyde, isopropanol which on standing for long time breaks into flower like structure. This test initially involves oxidation followed by substitution and hydrolysis [6].
Add 1 gm of molybdic acid in 25 ml of a concentrated sulfuric acid which has the reagent. Mix 2 ml of this reagent when hot and with 2 ml of distillate. At the junction of both liquids, a ring will be formed which is deep blue in color. On shaking, the whole mixture will become deep blue which is due to ethyl alcohol. This test is very sensitive and it gives a negative result with acetone, acetaldehyde, and dilute solution of methyl alcohol. Only the strong solution of methyl alcohol gives a light blue color after several minutes [6].
Mix two drops of benzoyl chloride with 2 ml of the distillate. Add 10% of sodium hydroxide drop by drop till the solution becomes alkaline. By providing heat the irritating smell of benzoyl chloride will be replaced by sweet fruity odor of ethyl benzoate. Methyl alcohol gives this test also but not the iodoform test [6].
In case of drunkenness, alcohol detection in the body is very important. Observing behavioral abnormalities of the suspect is the best method, but analyzing the breath, blood, and urine is the only way of confirming it. The analysis of breath alcohol can be performed on the spot with the help of breath-analyzer instruments like Alco-Sensor, Breathalyzer, etc. However, the alcohol content of the blood could be determined by using the modified version of the Kozelka and Hine/Cavett method [6].
In recent years, several methods in determining the alcohol in body fluids are described. Kent-Jones and Taylor reported the results of an investigation into the merits of two methods—the micro Cavett and that of Kozelka and Hine. The micro Cavett method is more accurate, but it suffered from serious inconsistencies in reproducibility, but the Kozelka and Hine method is less accurate and more time-consuming but gives good reproducibility.
Nickolls modified the micro Cavett method which appears to give a more accurate result in comparison with the unmodified method. The simplicity of this procedure increases its use for routine work in laboratory [8].
The principle behind this method is the oxidation of alcohol, which is easy with acetic acid in the presence of oxidizing agents such as sulfuric acid and potassium dichromate. Reduction of each mL of N/20 potassium dichromate solution takes place that is equivalent to 0.575 mg of alcohol [6].
This formula is used to estimate the amount in which alcohol is present in the body.
a. For blood analysis
Here, a = Total amount of alcohol absorbed in the body; p = Weight of the person; c = Concentration of alcohol in the blood; r = Constant which is 0.5 in women and 0.68 in men
b. In urine analysis.
Here, a = Total alcohol content present in the body; p = Total weight of the person; q = Alcohol concentration in the urine; r = Constant, namely, 0.68 for men and 0.5 in women [6].
There are several methods in determining ethanol in the blood, urine, and serum. One of the most important methods is gas chromatography (GC). The sample is injected in a heating chamber, and due to its high temperature, alcohol converts in vapors which are carried by inert carrier gas such as nitrogen through the column which is packed by an adsorbent material. Separation of different types of components depends on their different affinity, i.e., partition coefficient toward adsorbent phase which is stationary and later detected as shown in the figure below. A chromatogram so obtained helps in qualitative as well as quantitative analysis [6].
Various components of gas chromatography are [9]:
Carrier gas
Flow regulator
Injector
Column
Stationary phase
Oven
Detectors
Display device
The area covered by the peak represents the amount and position of a particular type of compound [6].
Operating conditions [10]:
Column: Porapak polymer bead 80–100 mesh or its equivalent, which can separate or resolve the ethanol.
Column temperature: 1600°C.
Carrier gas: Nitrogen.
Rate of gas flow: 50 ml/minute.
Detector: Flame ionization detector.
Alternative operating conditions:
Column: 0.3% Carbowax 20 M on 80–100 mesh Carbopak C, 2 m × 2 mm ID or its equivalent.
Column temperature: 350°C for 2 minutes and then programmed at 50°C per minute to 1750°C and hold for at least 8 minutes.
Carrier gas: Nitrogen at 30 ml/minute [6].
The purpose of this chapter is to discuss the mode of action and function of poisons once they reached in the human body. The impacts of poisons are severe and even cause death if not treated properly.
Customer Satisfaction is of paramount importance at IntechOpen and we take all complaints very seriously. Our Authors, their institutions, and other purchasers, if dissatisfied with the service provided, or the product purchased, can file a written complaint to IntechOpen, 5 Princes Gate Court, London, SW7 2QJ, UK or via the following e-mail address: info@intechopen.com.
',metaTitle:"Customer Complaints",metaDescription:"Our authors, their institutions and other purchasers, if unsatisfied with the service provided or the product purchased, can file a written complaint at IN TECH d.o.o offices at Janeza Trdine 9, 51000 Rijeka, Croatia, or via the following e-mail address: info@intechopen.com.",metaKeywords:null,canonicalURL:null,contentRaw:'[{"type":"htmlEditorComponent","content":"Receipt of complaints will be acknowledged in writing and Intech Limited will respond fully to concerns within 15 business days.
\\n\\nCustomers have the right to terminate the contract without giving any reason (written notice of termination). The deadline for said termination is fourteen (14) days from the date of receipt of goods. Returns are at the expense of the Customer and must be made within the fourteen (14) days from the date of the written notice of termination. Intech Limited will process refunds to the Customer without undue delay.
\\n\\nIn the event that the Publisher ships damaged or misbound copies of products, or duplicate or incorrect copies of the products are received by the Customer, the Publisher will accept returns at the Publisher's expense, provided notice of such damaged or incorrect shipment is given to the Publisher within fourteen (14) working days from the date of receipt.
\\n\\nPublishing errors, including but not limited to typographical errors, having no significant effect on the editorial content or design characteristics of the products, cannot be considered a reason for rejecting payment or, as the case may be, modifying the agreed price.
\\n\\nAt the Publisher's request, the customer should provide evidence of the damaged or incorrect shipment. The Publisher will refund or ship the ordered products without delays.
\\n"}]'},components:[{type:"htmlEditorComponent",content:"Receipt of complaints will be acknowledged in writing and Intech Limited will respond fully to concerns within 15 business days.
\n\nCustomers have the right to terminate the contract without giving any reason (written notice of termination). The deadline for said termination is fourteen (14) days from the date of receipt of goods. Returns are at the expense of the Customer and must be made within the fourteen (14) days from the date of the written notice of termination. Intech Limited will process refunds to the Customer without undue delay.
\n\nIn the event that the Publisher ships damaged or misbound copies of products, or duplicate or incorrect copies of the products are received by the Customer, the Publisher will accept returns at the Publisher's expense, provided notice of such damaged or incorrect shipment is given to the Publisher within fourteen (14) working days from the date of receipt.
\n\nPublishing errors, including but not limited to typographical errors, having no significant effect on the editorial content or design characteristics of the products, cannot be considered a reason for rejecting payment or, as the case may be, modifying the agreed price.
\n\nAt the Publisher's request, the customer should provide evidence of the damaged or incorrect shipment. The Publisher will refund or ship the ordered products without delays.
\n"}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5774},{group:"region",caption:"Middle and South America",value:2,count:5240},{group:"region",caption:"Africa",value:3,count:1721},{group:"region",caption:"Asia",value:4,count:10411},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15812}],offset:12,limit:12,total:118381},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"dateEndThirdStepPublish",topicId:"6,5"},books:[{type:"book",id:"9662",title:"Vegetation Index and Dynamics",subtitle:null,isOpenForSubmission:!0,hash:"0abf2a59ee63fc1ba4fb64d77c9b1be7",slug:null,bookSignature:"Dr. Eusebio Cano Carmona, Dr. Ricardo Quinto Canas, Dr. Ana Cano Ortiz and Dr. Carmelo Maria Musarella",coverURL:"https://cdn.intechopen.com/books/images_new/9662.jpg",editedByType:null,editors:[{id:"87846",title:"Dr.",name:"Eusebio",surname:"Cano Carmona",slug:"eusebio-cano-carmona",fullName:"Eusebio Cano Carmona"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9659",title:"Fibroblasts - Advances in Cancer, Autoimmunity and Inflammation",subtitle:null,isOpenForSubmission:!0,hash:"926fa6446f6befbd363fc74971a56de2",slug:null,bookSignature:"Ph.D. Mojca Frank Bertoncelj and Ms. Katja Lakota",coverURL:"https://cdn.intechopen.com/books/images_new/9659.jpg",editedByType:null,editors:[{id:"328755",title:"Ph.D.",name:"Mojca",surname:"Frank Bertoncelj",slug:"mojca-frank-bertoncelj",fullName:"Mojca Frank Bertoncelj"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8977",title:"Protein Kinase - New Opportunities, Challenges and Future Perspectives",subtitle:null,isOpenForSubmission:!0,hash:"6d200cc031706a565b554fdb1c478901",slug:null,bookSignature:"Dr. Rajesh Kumar Singh",coverURL:"https://cdn.intechopen.com/books/images_new/8977.jpg",editedByType:null,editors:[{id:"329385",title:"Dr.",name:"Rajesh",surname:"Singh",slug:"rajesh-singh",fullName:"Rajesh Singh"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10557",title:"Elaeis guineensis",subtitle:null,isOpenForSubmission:!0,hash:"79500ab1930271876b4e0575e2ed3966",slug:null,bookSignature:"Dr. Hesam Kamyab",coverURL:"https://cdn.intechopen.com/books/images_new/10557.jpg",editedByType:null,editors:[{id:"225957",title:"Dr.",name:"Hesam",surname:"Kamyab",slug:"hesam-kamyab",fullName:"Hesam Kamyab"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10218",title:"Flagellar Motility in Cells",subtitle:null,isOpenForSubmission:!0,hash:"5fcc15570365a82d9f2c4816f4e0ee2e",slug:null,bookSignature:"Prof. Yusuf Bozkurt",coverURL:"https://cdn.intechopen.com/books/images_new/10218.jpg",editedByType:null,editors:[{id:"90846",title:"Prof.",name:"Yusuf",surname:"Bozkurt",slug:"yusuf-bozkurt",fullName:"Yusuf Bozkurt"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10750",title:"Solanum tuberosum - a Promising Crop for Starvation Problem",subtitle:null,isOpenForSubmission:!0,hash:"516eb729eadf0d1a9d1d2e6bf31e8e9c",slug:null,bookSignature:"Prof. Mustafa Yildiz and Dr. Yasin Ozgen",coverURL:"https://cdn.intechopen.com/books/images_new/10750.jpg",editedByType:null,editors:[{id:"141637",title:"Prof.",name:"Mustafa",surname:"Yildiz",slug:"mustafa-yildiz",fullName:"Mustafa Yildiz"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10797",title:"Cell Culture",subtitle:null,isOpenForSubmission:!0,hash:"2c628f4757f9639a4450728d839a7842",slug:null,bookSignature:"Prof. Xianquan Zhan",coverURL:"https://cdn.intechopen.com/books/images_new/10797.jpg",editedByType:null,editors:[{id:"223233",title:"Prof.",name:"Xianquan",surname:"Zhan",slug:"xianquan-zhan",fullName:"Xianquan Zhan"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10772",title:"Parasitic Plants",subtitle:null,isOpenForSubmission:!0,hash:"31abd439b5674c91d18ad77dbc52500f",slug:null,bookSignature:"Dr. Ana Maria Gonzalez and Dr. Hector Sato",coverURL:"https://cdn.intechopen.com/books/images_new/10772.jpg",editedByType:null,editors:[{id:"281854",title:"Dr.",name:"Ana Maria",surname:"Gonzalez",slug:"ana-maria-gonzalez",fullName:"Ana Maria Gonzalez"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10737",title:"Equus",subtitle:null,isOpenForSubmission:!0,hash:"258ffafc92a7c9550bb85f004d7402e7",slug:null,bookSignature:"Associate Prof. Adriana Pires Neves",coverURL:"https://cdn.intechopen.com/books/images_new/10737.jpg",editedByType:null,editors:[{id:"188768",title:"Associate Prof.",name:"Adriana",surname:"Pires Neves",slug:"adriana-pires-neves",fullName:"Adriana Pires Neves"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10777",title:"Plant Reproductive Ecology - Recent Advances",subtitle:null,isOpenForSubmission:!0,hash:"3fbf391f2093649bcf3bd674f7e32189",slug:null,bookSignature:"Dr. Balkrishna Ghimire",coverURL:"https://cdn.intechopen.com/books/images_new/10777.jpg",editedByType:null,editors:[{id:"206647",title:"Dr.",name:"Balkrishna",surname:"Ghimire",slug:"balkrishna-ghimire",fullName:"Balkrishna Ghimire"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10749",title:"Legumes",subtitle:null,isOpenForSubmission:!0,hash:"49d3123cde96adbe706adadebebc5ebb",slug:null,bookSignature:"Dr. Jose Carlos Jimenez-Lopez",coverURL:"https://cdn.intechopen.com/books/images_new/10749.jpg",editedByType:null,editors:[{id:"33993",title:"Dr.",name:"Jose Carlos",surname:"Jimenez-Lopez",slug:"jose-carlos-jimenez-lopez",fullName:"Jose Carlos Jimenez-Lopez"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10751",title:"Bovine Science",subtitle:null,isOpenForSubmission:!0,hash:"9e3eb325f9fce20e6cefbce1c26d647a",slug:null,bookSignature:"Dr. Muhammad Abubakar",coverURL:"https://cdn.intechopen.com/books/images_new/10751.jpg",editedByType:null,editors:[{id:"112070",title:"Dr.",name:"Muhammad",surname:"Abubakar",slug:"muhammad-abubakar",fullName:"Muhammad Abubakar"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:19},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:5},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:8},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:21},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:6},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:25},{group:"topic",caption:"Neuroscience",value:18,count:2},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:24},popularBooks:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5252},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editedByType:"Edited by",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editedByType:"Edited by",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editedByType:"Edited by",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editedByType:"Edited by",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9669",title:"Recent Advances in Rice Research",subtitle:null,isOpenForSubmission:!1,hash:"12b06cc73e89af1e104399321cc16a75",slug:"recent-advances-in-rice-research",bookSignature:"Mahmood-ur- Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/9669.jpg",editedByType:"Edited by",editors:[{id:"185476",title:"Dr.",name:"Mahmood-Ur-",middleName:null,surname:"Rahman Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-Ur- Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editedByType:"Edited by",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"23",title:"Social Sciences",slug:"social-sciences",parent:{title:"Social Sciences and Humanities",slug:"social-sciences-and-humanities"},numberOfBooks:87,numberOfAuthorsAndEditors:1355,numberOfWosCitations:542,numberOfCrossrefCitations:429,numberOfDimensionsCitations:841,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"social-sciences",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editedByType:"Edited by",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9043",title:"Parenting",subtitle:"Studies by an Ecocultural and Transactional Perspective",isOpenForSubmission:!1,hash:"6d21066c7438e459e4c6fb13217a5c8c",slug:"parenting-studies-by-an-ecocultural-and-transactional-perspective",bookSignature:"Loredana Benedetto and Massimo Ingrassia",coverURL:"https://cdn.intechopen.com/books/images_new/9043.jpg",editedByType:"Edited by",editors:[{id:"193200",title:"Prof.",name:"Loredana",middleName:null,surname:"Benedetto",slug:"loredana-benedetto",fullName:"Loredana Benedetto"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6934",title:"Psycho-Social Aspects of Human Sexuality and Ethics",subtitle:null,isOpenForSubmission:!1,hash:"44731b106aa0d1ab5c64a7394483c7d5",slug:"psycho-social-aspects-of-human-sexuality-and-ethics",bookSignature:"Dhastagir Sultan Sheriff",coverURL:"https://cdn.intechopen.com/books/images_new/6934.jpg",editedByType:"Edited by",editors:[{id:"167875",title:"Dr.",name:"Dhastagir Sultan",middleName:null,surname:"Sheriff",slug:"dhastagir-sultan-sheriff",fullName:"Dhastagir Sultan Sheriff"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editedByType:"Edited by",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editedByType:"Edited by",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9251",title:"Pleistocene Archaeology",subtitle:"Migration, Technology, and Adaptation",isOpenForSubmission:!1,hash:"65e1040ad23f0385a56f2d0472b4aee5",slug:"pleistocene-archaeology-migration-technology-and-adaptation",bookSignature:"Rintaro Ono and Alfred Pawlik",coverURL:"https://cdn.intechopen.com/books/images_new/9251.jpg",editedByType:"Edited by",editors:[{id:"177123",title:"Ph.D.",name:"Rintaro",middleName:null,surname:"Ono",slug:"rintaro-ono",fullName:"Rintaro Ono"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8090",title:"Who Wants to Retire and Who Can Afford to Retire?",subtitle:null,isOpenForSubmission:!1,hash:"90fe30d224594414bb156e42afa47f5e",slug:"who-wants-to-retire-and-who-can-afford-to-retire-",bookSignature:"Ingrid Muenstermann",coverURL:"https://cdn.intechopen.com/books/images_new/8090.jpg",editedByType:"Edited by",editors:[{id:"77112",title:"Dr.",name:"Ingrid",middleName:null,surname:"Muenstermann",slug:"ingrid-muenstermann",fullName:"Ingrid Muenstermann"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10032",title:"Fire Safety and Management Awareness",subtitle:null,isOpenForSubmission:!1,hash:"ba924ac3ec282316ae8ba97882cc4592",slug:"fire-safety-and-management-awareness",bookSignature:"Fahmina Zafar and Anujit Ghosal",coverURL:"https://cdn.intechopen.com/books/images_new/10032.jpg",editedByType:"Edited by",editors:[{id:"89672",title:"Dr.",name:"Fahmina",middleName:null,surname:"Zafar",slug:"fahmina-zafar",fullName:"Fahmina Zafar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7806",title:"Public Sector Crisis Management",subtitle:null,isOpenForSubmission:!1,hash:"84a998820880e0f006a5e9eac40d83e7",slug:"public-sector-crisis-management",bookSignature:"Alexander Rozanov, Alexander Barannikov, Olga Belyaeva and Mikhail Smirnov",coverURL:"https://cdn.intechopen.com/books/images_new/7806.jpg",editedByType:"Edited by",editors:[{id:"233092",title:"Dr.",name:"Alexander",middleName:null,surname:"Rozanov",slug:"alexander-rozanov",fullName:"Alexander Rozanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9256",title:"Risk Management and Assessment",subtitle:null,isOpenForSubmission:!1,hash:"b5547d1d68d2db6f22eedb8f306b0276",slug:"risk-management-and-assessment",bookSignature:"Jorge Rocha, Sandra Oliveira and César Capinha",coverURL:"https://cdn.intechopen.com/books/images_new/9256.jpg",editedByType:"Edited by",editors:[{id:"145918",title:"Ph.D.",name:"Jorge",middleName:null,surname:"Rocha",slug:"jorge-rocha",fullName:"Jorge Rocha"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7810",title:"Quality of Life",subtitle:"Biopsychosocial Perspectives",isOpenForSubmission:!1,hash:"0392d2712c58885b729bd943f9aac37f",slug:"quality-of-life-biopsychosocial-perspectives",bookSignature:"Floriana Irtelli, Federico Durbano and Simon George Taukeni",coverURL:"https://cdn.intechopen.com/books/images_new/7810.jpg",editedByType:"Edited by",editors:[{id:"174641",title:"Dr.",name:"Floriana",middleName:null,surname:"Irtelli",slug:"floriana-irtelli",fullName:"Floriana Irtelli"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6927",title:"Intellectual Property Rights",subtitle:"Patent",isOpenForSubmission:!1,hash:"9fd5884b3bce2ec6f77a8356ea384a37",slug:"intellectual-property-rights-patent",bookSignature:"Sakthivel Lakshmana Prabu, Suriyaprakash Tnk, Eduardo Jacob-Lopes and Leila Queiroz Zepka",coverURL:"https://cdn.intechopen.com/books/images_new/6927.jpg",editedByType:"Edited by",editors:[{id:"91590",title:"Dr.",name:"Sakthivel",middleName:null,surname:"Lakshmana Prabu",slug:"sakthivel-lakshmana-prabu",fullName:"Sakthivel Lakshmana Prabu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:87,mostCitedChapters:[{id:"42656",doi:"10.5772/55538",title:"Conceptual Frameworks of Vulnerability Assessments for Natural Disasters Reduction",slug:"conceptual-frameworks-of-vulnerability-assessments-for-natural-disasters-reduction",totalDownloads:8959,totalCrossrefCites:15,totalDimensionsCites:56,book:{slug:"approaches-to-disaster-management-examining-the-implications-of-hazards-emergencies-and-disasters",title:"Approaches to Disaster Management",fullTitle:"Approaches to Disaster Management - Examining the Implications of Hazards, Emergencies and Disasters"},signatures:"Roxana L. Ciurean, Dagmar Schröter and Thomas Glade",authors:[{id:"163703",title:"Prof.",name:"Thomas",middleName:null,surname:"Glade",slug:"thomas-glade",fullName:"Thomas Glade"},{id:"164141",title:"Ph.D. Student",name:"Roxana",middleName:"Liliana",surname:"Ciurean",slug:"roxana-ciurean",fullName:"Roxana Ciurean"},{id:"164142",title:"Dr.",name:"Dagmar",middleName:null,surname:"Schroeter",slug:"dagmar-schroeter",fullName:"Dagmar Schroeter"}]},{id:"45760",doi:"10.5772/56967",title:"Parenting and Culture – Evidence from Some African Communities",slug:"parenting-and-culture-evidence-from-some-african-communities",totalDownloads:8024,totalCrossrefCites:5,totalDimensionsCites:17,book:{slug:"parenting-in-south-american-and-african-contexts",title:"Parenting in South American and African Contexts",fullTitle:"Parenting in South American and African Contexts"},signatures:"Patricia Mawusi Amos",authors:[{id:"162496",title:"Mrs.",name:"Patricia",middleName:"Mawusi",surname:"Amos",slug:"patricia-amos",fullName:"Patricia Amos"}]},{id:"59705",doi:"10.5772/intechopen.74943",title:"Augmented Reality Trends in Education between 2016 and 2017 Years",slug:"augmented-reality-trends-in-education-between-2016-and-2017-years",totalDownloads:1660,totalCrossrefCites:14,totalDimensionsCites:17,book:{slug:"state-of-the-art-virtual-reality-and-augmented-reality-knowhow",title:"State of the Art Virtual Reality and Augmented Reality Knowhow",fullTitle:"State of the Art Virtual Reality and Augmented Reality Knowhow"},signatures:"Rabia M. Yilmaz",authors:[{id:"225838",title:"Dr.",name:"Rabia",middleName:null,surname:"Yilmaz",slug:"rabia-yilmaz",fullName:"Rabia Yilmaz"}]}],mostDownloadedChaptersLast30Days:[{id:"58890",title:"Philosophy and Paradigm of Scientific Research",slug:"philosophy-and-paradigm-of-scientific-research",totalDownloads:8640,totalCrossrefCites:2,totalDimensionsCites:3,book:{slug:"management-culture-and-corporate-social-responsibility",title:"Management Culture and Corporate Social Responsibility",fullTitle:"Management Culture and Corporate Social Responsibility"},signatures:"Pranas Žukauskas, Jolita Vveinhardt and Regina Andriukaitienė",authors:[{id:"179629",title:"Prof.",name:"Jolita",middleName:null,surname:"Vveinhardt",slug:"jolita-vveinhardt",fullName:"Jolita Vveinhardt"}]},{id:"34156",title:"History and Sociology: What is Historical Sociology?",slug:"history-and-sociology-what-is-historical-sociology-",totalDownloads:14888,totalCrossrefCites:2,totalDimensionsCites:2,book:{slug:"sociological-landscape-theories-realities-and-trends",title:"Sociological Landscape",fullTitle:"Sociological Landscape - Theories, Realities and Trends"},signatures:"Jiri Subrt",authors:[{id:"119641",title:"Dr",name:null,middleName:null,surname:"Subrt",slug:"subrt",fullName:"Subrt"}]},{id:"58060",title:"Pedagogy of the Twenty-First Century: Innovative Teaching Methods",slug:"pedagogy-of-the-twenty-first-century-innovative-teaching-methods",totalDownloads:6971,totalCrossrefCites:3,totalDimensionsCites:6,book:{slug:"new-pedagogical-challenges-in-the-21st-century-contributions-of-research-in-education",title:"New Pedagogical Challenges in the 21st Century",fullTitle:"New Pedagogical Challenges in the 21st Century - Contributions of Research in Education"},signatures:"Aigerim Mynbayeva, Zukhra Sadvakassova and Bakhytkul\nAkshalova",authors:[{id:"201997",title:"Dr.",name:"Aigerim",middleName:null,surname:"Mynbayeva",slug:"aigerim-mynbayeva",fullName:"Aigerim Mynbayeva"},{id:"209208",title:"Dr.",name:"Zukhra",middleName:null,surname:"Sadvakassova",slug:"zukhra-sadvakassova",fullName:"Zukhra Sadvakassova"},{id:"209210",title:"Dr.",name:"Bakhytkul",middleName:null,surname:"Akshalova",slug:"bakhytkul-akshalova",fullName:"Bakhytkul Akshalova"}]},{id:"52475",title:"Teenage Pregnancies: A Worldwide Social and Medical Problem",slug:"teenage-pregnancies-a-worldwide-social-and-medical-problem",totalDownloads:5902,totalCrossrefCites:4,totalDimensionsCites:4,book:{slug:"an-analysis-of-contemporary-social-welfare-issues",title:"An Analysis of Contemporary Social Welfare Issues",fullTitle:"An Analysis of Contemporary Social Welfare Issues"},signatures:"Sylvia Kirchengast",authors:[{id:"188289",title:"Prof.",name:"Sylvia",middleName:null,surname:"Kirchengast",slug:"sylvia-kirchengast",fullName:"Sylvia Kirchengast"}]},{id:"58894",title:"Research Ethics",slug:"research-ethics",totalDownloads:1874,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"management-culture-and-corporate-social-responsibility",title:"Management Culture and Corporate Social Responsibility",fullTitle:"Management Culture and Corporate Social Responsibility"},signatures:"Pranas Žukauskas, Jolita Vveinhardt and Regina Andriukaitienė",authors:[{id:"179629",title:"Prof.",name:"Jolita",middleName:null,surname:"Vveinhardt",slug:"jolita-vveinhardt",fullName:"Jolita Vveinhardt"}]},{id:"42656",title:"Conceptual Frameworks of Vulnerability Assessments for Natural Disasters Reduction",slug:"conceptual-frameworks-of-vulnerability-assessments-for-natural-disasters-reduction",totalDownloads:8954,totalCrossrefCites:15,totalDimensionsCites:56,book:{slug:"approaches-to-disaster-management-examining-the-implications-of-hazards-emergencies-and-disasters",title:"Approaches to Disaster Management",fullTitle:"Approaches to Disaster Management - Examining the Implications of Hazards, Emergencies and Disasters"},signatures:"Roxana L. Ciurean, Dagmar Schröter and Thomas Glade",authors:[{id:"163703",title:"Prof.",name:"Thomas",middleName:null,surname:"Glade",slug:"thomas-glade",fullName:"Thomas Glade"},{id:"164141",title:"Ph.D. Student",name:"Roxana",middleName:"Liliana",surname:"Ciurean",slug:"roxana-ciurean",fullName:"Roxana Ciurean"},{id:"164142",title:"Dr.",name:"Dagmar",middleName:null,surname:"Schroeter",slug:"dagmar-schroeter",fullName:"Dagmar Schroeter"}]},{id:"45760",title:"Parenting and Culture – Evidence from Some African Communities",slug:"parenting-and-culture-evidence-from-some-african-communities",totalDownloads:8013,totalCrossrefCites:5,totalDimensionsCites:17,book:{slug:"parenting-in-south-american-and-african-contexts",title:"Parenting in South American and African Contexts",fullTitle:"Parenting in South American and African Contexts"},signatures:"Patricia Mawusi Amos",authors:[{id:"162496",title:"Mrs.",name:"Patricia",middleName:"Mawusi",surname:"Amos",slug:"patricia-amos",fullName:"Patricia Amos"}]},{id:"52503",title:"Gender and Leadership",slug:"gender-and-leadership",totalDownloads:3103,totalCrossrefCites:4,totalDimensionsCites:7,book:{slug:"gender-differences-in-different-contexts",title:"Gender Differences in Different Contexts",fullTitle:"Gender Differences in Different Contexts"},signatures:"Kathryn E. Eklund, Erin S. Barry and Neil E. Grunberg",authors:[{id:"191531",title:"Dr.",name:"Neil",middleName:null,surname:"Grunberg",slug:"neil-grunberg",fullName:"Neil Grunberg"},{id:"191532",title:"Dr.",name:"Erin",middleName:null,surname:"Barry",slug:"erin-barry",fullName:"Erin Barry"},{id:"191533",title:"Ph.D. Student",name:"Kathryn",middleName:null,surname:"Eklund",slug:"kathryn-eklund",fullName:"Kathryn Eklund"}]},{id:"60813",title:"Crisis Management: A Historical and Conceptual Approach for a Better Understanding of Today’s Crises",slug:"crisis-management-a-historical-and-conceptual-approach-for-a-better-understanding-of-today-s-crises",totalDownloads:3191,totalCrossrefCites:1,totalDimensionsCites:3,book:{slug:"crisis-management-theory-and-practice",title:"Crisis Management",fullTitle:"Crisis Management - Theory and Practice"},signatures:"Khaled Zamoum and Tevhide Serra Gorpe",authors:[{id:"230918",title:"Prof.",name:"T. Serra",middleName:null,surname:"Gorpe",slug:"t.-serra-gorpe",fullName:"T. Serra Gorpe"},{id:"230920",title:"Dr.",name:"Khaled",middleName:null,surname:"Zamoum",slug:"khaled-zamoum",fullName:"Khaled Zamoum"}]},{id:"63707",title:"Drinking Water Treatment and Challenges in Developing Countries",slug:"drinking-water-treatment-and-challenges-in-developing-countries",totalDownloads:2761,totalCrossrefCites:6,totalDimensionsCites:9,book:{slug:"the-relevance-of-hygiene-to-health-in-developing-countries",title:"The Relevance of Hygiene to Health in Developing Countries",fullTitle:"The Relevance of Hygiene to Health in Developing Countries"},signatures:"Josephine Treacy",authors:[{id:"238173",title:"Dr.",name:"Josephine",middleName:null,surname:"Treacy",slug:"josephine-treacy",fullName:"Josephine Treacy"}]}],onlineFirstChaptersFilter:{topicSlug:"social-sciences",limit:3,offset:0},onlineFirstChaptersCollection:[{id:"75224",title:"Decoding the Digital Gap in Teacher Education: Three Perspectives across the Globe",slug:"decoding-the-digital-gap-in-teacher-education-three-perspectives-across-the-globe",totalDownloads:2,totalDimensionsCites:0,doi:"10.5772/intechopen.96206",book:{title:"Teacher Education in the 21st Century - Emerging Skills for a Changing World"},signatures:"Steinar Thorvaldsen and Siri Sollied Madsen"},{id:"75268",title:"How Philosophizing the Dialogos Way Can Promote Education for Sustainable Development",slug:"how-philosophizing-the-dialogos-way-can-promote-education-for-sustainable-development",totalDownloads:0,totalDimensionsCites:0,doi:"10.5772/intechopen.96198",book:{title:"Teacher Education in the 21st Century - Emerging Skills for a Changing World"},signatures:"Eirik Hæreid Marcussen, Michael Weiss and Guro Hansen Helskog"},{id:"75591",title:"Quality Inclusion of Young Children with Disabilities: Taking a Stance to Support Early Childhood Leaders",slug:"quality-inclusion-of-young-children-with-disabilities-taking-a-stance-to-support-early-childhood-lea",totalDownloads:0,totalDimensionsCites:0,doi:"10.5772/intechopen.96511",book:{title:"Teacher Education in the 21st Century - Emerging Skills for a Changing World"},signatures:"Sara Movahedazarhouligh"}],onlineFirstChaptersTotal:55},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/133716/hanifa-boucheneb",hash:"",query:{},params:{id:"133716",slug:"hanifa-boucheneb"},fullPath:"/profiles/133716/hanifa-boucheneb",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()